Patterns and Predictors of Healthcare Use among Adolescent and Young Adult Cancer Survivors versus a Community Comparison Group

Ursula M. Sansom-Daly 1,2,3,* 1, Claire E. Wakefield 1,2,4, Christina Signorelli 1,2,5, Mark W. Donoghoe 1,2,4, Antoinette Anazodo 1,2,6, Susan M. Sawyer 5,6,7, Michael Osborn 8, Rosalie Viney 9, Nicholas Daniell 2, Kate Faasse 10 and Richard J. Cohn 1,2

Cancers 2021, 13, 5270. https://doi.org/10.3390/cancers13215270

Abstract: Healthcare use (HCU) during survivorship can mitigate adolescent and young adult (AYA) cancer survivors’ (aged 15–39 years) risk of medical and psychosocial late effects, but this is understudied. We surveyed 93 Australian AYA post-treatment cancer survivors (Mage = 22.0 years, SD = 3.5; 55.9% female) and a comparison sample of 183 non-matched AYAs (Mage = 19.7, SD = 3.2; 70.5% female) on their HCU, medication use, depression/anxiety, and general functioning. Relative to our comparison AYAs, a higher proportion of our survivor group reported greater use of medical and mental health services, and medications during the past six months relative to the comparison group. Our cancer survivor group also reported greater use of medical and psychosocial late effects following cancer treatment. These effects may be minimized through healthcare use tailored to young survivors’ needs. Future research is needed to determine whether the healthcare accessed by adolescent and young adult cancer survivors is appropriate and meets their needs.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Cancers 2021, 13, 5270

2 of 28

HCU (p = 0.001). Among survivors, those who were female, diagnosed with brain/solid tumors and who had finished treatment more recently reported greater HCU. Future research should establish whether this level of HCU meets AYAs’ survivorship needs.

Keywords: cancer survivorship; cancer survivors; survivorship; healthcare utilization; adolescent; young adult; neoplasms/psychology; mental health services; psychosocial factors; psychotropic medication

1. Introduction

The diagnosis of cancer in an adolescent or young adult (AYA, aged 15–39 years consistent with the broadest global definition) risks fundamentally disrupting their developmental trajectory towards adulthood [1–3], compounded by adolescence and young adulthood being the life stage across which mental health disorders are most likely to emerge [4]. Worldwide, over one million AYAs grapple with this new reality each year [5]. Fortunately, international estimates suggest that up to 88% can expect to survive their disease and move towards longer-term survivorship and life as an adult [5]. This means that ensuring the physical and mental health and well-being of young cancer survivors is an important priority.

AYAs face a range of complex physical and psychosocial late effects that can last decades following completion of cancer treatment. This includes physical late effects (e.g., endocrine and cardiopulmonary damage) [6], the potential for recurrent or second primary cancers [7,8], complex mental health effects including depression, anxiety, post-traumatic stress [3,9,10], and higher rates of fear of cancer recurrence than older patients [11,12]. AYAs’ young age at diagnosis means that the impact of their physical and mental health late effects on their general functioning in survivorship can be profound. Economic data from Australia show that the loss of productivity and future potential among AYA cancer patients diagnosed every year costs the economy an estimated AU $455 million in lifetime costs, far eclipsing the cost of the cancer treatment itself [13].

In addition to AYA survivors’ profile of psychological late effects, their lack of high-level health literacy [14] and documented desire to avoid mental health-related stigma [15] may impact how they access and interact with healthcare services [16]. International consensus supports the idea that AYAs living with and beyond cancer may benefit from tailored, age-appropriate healthcare services to address their unique needs [17–23]. Indeed, AYAs report desiring healthcare services that are tailored to their developmental needs [24,25]. Better understanding by AYAs of their unique risk profile for treatment-related late effects and cancer recurrence and timely access to specialist AYA services may also minimize the burden of future physical and psychological late effects [26–28]. Engaging AYAs in age-appropriate, tailored, multidisciplinary survivorship care is therefore key to ensuring their physical and mental health as they mature.

In Australia, cancer survivors in the AYA age range are typically managed either by ‘long-term’ follow-up clinics based within pediatric (children’s) hospitals for long-term survivors (beyond five years post-diagnosis) [27,29], or through the survivorship clinics of the national network of Youth Cancer Services [30]. The Youth Cancer Services provide survivorship care tailored to AYAs diagnosed between the ages of 15 and 25 years, across pediatric hospitals (for AYAs diagnosed between 15 and 17 years old) and adult hospitals (for AYAs diagnosed at 18 years and older) [30]. The positive, age-appropriate communication and support experiences that these services can facilitate appear to lead to improved quality of life [21,24,31] and may foster greater engagement into long-term cancer survivorship than traditional, medically-driven models of care by accounting for the particular psychosocial needs of AYAs [27,29,32–35].

Existing research has focused on quantifying the impact of youth-friendly, age-appropriate healthcare for AYAs during active cancer treatment. Less research has reported on the healthcare services accessed by AYA cancer survivors after cancer treatment comple-
tion and further into survivorship [26]. More data are currently available about long-term survivors of childhood cancer, up to three-quarters of whom appear not to use recommended, cancer-related follow-up services [26,29]. Review data recently identified that while 65% of long-term childhood cancer survivors engaged in some form of healthcare use in relation to their survivorship (HCU), this ranged considerably, from 36 to 89% [26]. Survivors who were female, had received radiation therapy, were further from diagnosis, and who reported having a higher income, greater educational attainment, and higher self-reported health-related quality of life reported increased HCU [26].

Individual factors accounting for which AYAs engage with what types of health services in survivorship also remain largely unexplored. One early study reported that AYA cancer survivors who identified more closely with the term ‘cancer survivor’ were more likely to access professional mental health services [36]. This suggests that elements related to how AYAs have psychologically responded to their cancer experience may be reflected in their patterns of HCU. There are documented impacts of the diagnosis, treatment, and symptoms of cancer on AYAs’ later education and occupational productivity and attainment [2,37]. However, little research has examined patterns of HCU, mental health, and survivor functioning in these domains. Consequently, it remains unclear whether and how AYAs’ well-being and general functioning in survivorship is associated with the extent to which they access specialized medical and supportive services following their cancer treatment.

This study aimed to examine how a cohort of Australian AYA cancer survivors accessed healthcare to inform how services might best support AYAs to engage with developmentally-appropriate healthcare in survivorship. We anticipate that these data can inform how both hospital-delivered, AYA-specific health services and community-delivered (generalist) health services might be better tailored to target the most ‘at risk’ survivors, and most effectively mitigate the potential for adverse medical and psychological late effects. Given the predominant literature is from North America with a particular set of barriers to HCU [26], it is also important to report on how AYA survivors are faring and functioning in countries with different healthcare systems.

With reference to a locally-recruited, community-based comparison group, we aimed to describe AYA cancer survivors’ (1) overall HCU, (2) medical HCU (e.g., oncologist, general practitioner (GP), nurse consultations), (3) mental HCU (e.g., psychologist, social worker, psychiatrist consultations), and (4) medication use. Across each outcome, we examined whether individual differences according to sociodemographic and cancer-related factors were associated with HCU. Finally, we examined whether (5) the extent to which AYA cancer survivors engage in HCU in survivorship was associated with their subsequent general functioning, quality of life, or mental health.

2. Materials and Methods

This cross-sectional study was approved by the South Eastern Sydney Local Health District (SESLHD) Human Research Ethics Committee (Reference: HREC/12/POWH/136) as well as the Human Research Ethics Advisory Panel C (Behavioural Sciences), UNSW Sydney (File 2892).

2.1. Eligibility Criteria

In order to capture diverse cancer survivorship experiences and broad representation of the spectrum of HCU in AYAs surviving cancer, we recruited AYAs currently aged 15–39 years old, consistent with the broadest international definition [38], all of whom had completed cancer treatment at least one month prior, consistent with a post-treatment definition of ‘survivorship’. AYAs could have been diagnosed prior to the age of 15 but were now in the AYA age group. We included AYAs recruited from two survivorship clinics at a major metropolitan pediatric/AYA cancer service, including a post-treatment follow-up clinic and a long-term survivorship cohort (which provides survivorship care for survivors beyond five years post-diagnosis). We also recruited a convenience sample of
AYAs aged 15–39 years with no history of cancer from the local community to function as a comparison group (see below). AYAs who did not have sufficient English language skills to complete the questionnaire were ineligible.

2.2. Recruitment

We invited AYA cancer survivors through the Sydney Children’s Hospital, Australia long-term follow-up clinic lists, as well as the Sydney Youth Cancer Service patient database which also included patients from Prince of Wales Hospital Australia. We mailed cancer survivor participants a study package including a personalized invitation letter from an oncologist at that site, information sheet, consent form and questionnaire. Participants had the option to complete the questionnaire either on paper or using an online link.

We recruited our community-based comparison group of AYAs with no history of cancer through several sources, including undergraduate psychology students who participated in return for partial course credit, as well as through poster advertisements displayed on a local university campus (UNSW Sydney), a local gymnasium frequently attended by high-school students, and through the newsletters of several local public and private high schools. This convenience sample was drawn from the same geographical area as the cancer survivor cohort but was not matched for any other characteristics. This pragmatic recruitment strategy was designed to obtain a comparison AYA sample that was geographically well-matched, but did not strictly control for matching on other variables such as age (with our comparison AYAs recruited from local educational institutions more likely to be younger in age). We sent interested community participants who responded to the advertisement a study package containing an invitation letter, participant information sheet and consent form, and study questionnaire.

2.3. Measures

A multidisciplinary team of psychologists, oncologists, and health economists purposely designed the questionnaire which assessed AYAs’ health service and medication use, as well as general functioning (including participation in work/study and other productive activities), quality of life, and mental health. Table 1 summarizes the battery of measures used.

Table 1. Battery of self-reported measures used.

| Domain                        | Measure and Subscale Information                                                                 | Scoring and Analysis Information                                                                 | Psychometric Validity Data Available                                      |
|-------------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Demographic characteristics   | Adolescents and young adults (AYAs) age, sex, level of educational attainment, employment status, family structure, cancer diagnosis, treatment regimen | We dichotomized reported educational attainment (achievement below or at/above Year 12, the final year of high school in Australia) and cancer diagnosis (grouping blood cancers [i.e., leukemias, lymphomas] vs. all other cancer types [i.e., brain/solid tumors].) | -                                                                         |
| Mental health                 | Depression, Anxiety, Stress Scales-21 item short form (DASS-21): depression (7 item) and anxiety (7 item) subscales | 4-point scale, rating extent to which they had experienced each symptom in the past week (0 = “Did not apply to me at all—NEVER” to 3 = “Applied to me very much, or most of the time—ALMOST ALWAYS”). Higher responses indicate more severe symptoms. | Used in Australian adolescents [39], cancer patients [40] and AYAs [39,41], with strong internal consistency and reliability [39,41]. |
Table 1. Cont.

| Domain                                      | Measure and Subscale Information                                                                                                                                                                                                 | Scoring and Analysis Information                                                                                                                                                                                                 | Psychometric Validity Data Available |
|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------|
| Health-related quality of life              | Short Form-Six Dimension (SF6D): a six-dimensional health status classification derived from the 36-Item Short Form Health Survey (SF-36) questionnaire [42]                                                            | Measures self-reported overall perceived health status, on a 5-item scale (“In general, would you say your health is: . . poor, fair, good, very good, excellent”). For the purposes of analysis, we dichotomized participants’ responses into a binary outcome (fair-poor, good-excellent). | The use of this single item is a common approach to minimize participant burden and is considered valid, sensitive and reliable [43] |
| General functioning                         | Time taken off from study/work. Reasons included “Sickness or feeling unwell”, “Tiredness or low energy”, “Low motivation or ‘feeling flat’”, “Medical or health-related appointments”, “Unable to keep up with the workload”, “Self-conscious about physical scars or changes”, “Difficulty getting on with friends/colleagues”, and “Other”                                                   | Estimated days absent over the past 4 weeks, and the main reasons for this. Where participants selected “Other” they were asked to specify this in free-text.                                                                            | -                                    |
| Self-reported healthcare use (HCU) for survivorship support | Engagement with productive activities: including ‘Paid work of any kind’, ‘Study or learning of any kind (school, university, TAFE, other courses)’, ‘Exercise or sports’, ‘Personal hobbies (e.g., art, music, films, books, outdoor activities, cooking)’, ‘Socializing with friends’, and ‘Socializing with other young people [with cancer] (includes connecting online)’ (study-developed) | Estimated days engaged in any of these productive activities over the past 4 weeks. Engagement in productive activities: the item “Socialising with other young people with cancer (includes connecting online)” was reworded so as not to refer to cancer for control participants. | -                                    |
|                                             | Medical HCU: included seeing a general practitioner, oncologist/radiation oncologist, nurse in hospital, nurse in community, or fertility specialist. Hospital-delivered HCU: emergency department visits or hospital admissions. Mental HCU: included psychologists, social workers, counselors, psychiatrists, and community-delivered cancer support and/or mental health support organizations | Health professionals/services accessed for support over the past six months. For the purposes of our analysis, participants’ health services use was assessed according to frequency of use (not cost) by profession, as well as across total, general, and mental health service use categories. | -                                    |
|                                             | Medication use: Any medications/supplements taken, and the reasons for their use, over the past six months. Participants were not limited to listing only prescribed medications but were encouraged to omit very occasional medication use (e.g., an occasional dose of paracetamol) | Free-text response. Use was reported according to the number and classification of medications (not cost). The classification of these medications was manually checked by a senior pediatric oncologist (author RJC), with reference to the Monthly Index of Medical Specialties online database. | -                                    |
2.4. Data Analysis

We compared participants’ demographic characteristics across groups (cancer survivors vs. comparisons) using independent t-tests and chi-squared tests for continuous variables and categorical variables, respectively. We performed Pearson chi-squared tests on the proportion of AYAs accessing each type of healthcare service.

We then examined two aspects of survivors’ HCU: their overall access (whether or not they had ever used a particular service in the 6 month period; a binary yes/no outcome), and their intensity of use (how many service types or occasions of service within a particular healthcare service category they had accessed in that period; a continuous outcome). For simple descriptive summaries of HCU according to survivors’ time since treatment-completion, we categorized survivors according to whether they were in their first, second-fourth, or fifth year and beyond treatment completion (i.e., long-term cancer survivorship) as each of these stages has distinct healthcare-related needs and recommendations for surveillance and follow-up care. In subsequent regression analyses, we used time since diagnosis as a continuous predictor variable in order to retain information that would be lost through categorizing [44]. We categorized survivors’ age at diagnosis according to whether they were diagnosed at a ‘pediatric age’ (under 15 years) or as an ‘AYA’ (15 years and older, the age where AYAs with cancer are typically managed through AYA-specific Youth Cancer Services in Australia).

To investigate overall access, we used multivariable binary logistic regression analyses to investigate factors associated with AYA cancer survivors’ HCU. We included several sociodemographic and cancer-related variables associated with AYA survivorship needs and outcomes as covariates across all regression models. Several additional binary predictor variables were created from participant demographics to facilitate logistic regressions predicting AYAs’ likelihood of reporting HCU across the five categories above (see Table 1). Multicollinearity tests were undertaken at the outset to avoid problematic collinearity between these independent predictors. The variance inflation factor (VIF) was examined for each independent variable with a VIF \( \leq 3 \) considered acceptable. Problematic multicollinearity emerged between education status, and age at diagnosis and time since treatment; we therefore removed education as a predictor because its association with HCU was not of primary interest compared to obtaining more precise estimates of the other variable coefficients in the model. Consequently, our final analyses included these covariates: sex, employment status, speaking a language other than English at home, age at cancer diagnosis, diagnosis category (blood cancer vs. not), and time since treatment completion.

We used these predictors to examine HCU according to the following categories within logistic regression models (i) overall HCU, (ii) medical HCU (including GP, oncologist, nurse, fertility specialist and hospital Emergency Department visits, as well as any hospital admissions), (iii) hospital-delivered HCU only (hospital Emergency Department visits, as well as any hospital admissions only), (iv) mental HCU (including psychologist, psychiatrist, social worker, counsellor, and community-delivered support), and (v) medication use. Medication data were categorized according to any use, and number of medications taken, with medication and supplement use categorized according to the Monthly Index for Medical Specialties (MIMS) Online Database.

We used these same predictor variables within subsequent Poisson regression models to examine the extent to which these sociodemographic and cancer-related variables accounted for survivors’ total number of self-reported healthcare service use within each of these same HCU categories.

Finally, in order to examine whether AYAs’ extent of engagement with HCU during the past six months was associated with their current health-related quality of life or general functioning, multivariable linear regression analyses were carried out that accounted for sociodemographic and cancer-related factors. Given the relative lack of data in this area, we took a hypothesis-generating approach, and did not control for multiple comparisons.
3. Results

3.1. Participant Characteristics

We recruited 276 AYAs (93 cancer survivors, 183 comparison AYAs) prior to the onset of the global Coronavirus (COVID-19) pandemic. We were not able to calculate a response rate in either sample due to our use of open advertisements in recruiting our community-based comparison group, and ethical approval restrictions from having recruited cancer survivors across multiple hospitals [45].

Table 2 depicts participant characteristics by group. Cancer survivors were 22.0 years old on average (SD = 3.5), with a median age at diagnosis of 16 years (range: 0–27 years; Table 2). The cancer diagnoses represented were broadly representative of recent national registry-based data [46], with a slight over-representation of blood cancers relative to typical AYA patient samples, which will to some extent reflect our recruitment from a pool of AYA-aged cancer survivors diagnosed before 15 years old. Approximately two-thirds of the sample were within five years post-diagnosis. Due to the pragmatic, convenience-sampling approach we took in recruiting our comparison group, they were slightly younger (M age = 19.7, SD = 3.2 vs. M age = 21.9 years, SD = 3.5; *p* < 0.001), and had a higher proportion of female respondents (70.5% vs. 55.9%, *p* = 0.036). Our comparison AYAs also had lower proportions who had completed post-high-school education (12.6% vs. 51.6%; *p* < 0.001), but more who were currently studying or employed (94.5% vs. 87.1%; *p* = 0.031) relative to the AYA cancer survivors.

Table 2. Participant sociodemographic characteristics across groups.

|                                      | Cancer Survivors (n = 93) | Comparison (n = 183) | Total (n = 276) | *p*-Value |
|--------------------------------------|---------------------------|----------------------|----------------|-----------|
| Age (range: 15–31 years)—M (SD)      | 21.9 (3.53)               | 19.7 (3.16)          | 20.5 (3.44)    | <0.001    |
| Sex                                  | Female 52 (55.9%)         | 129 (70.5%)          | 181 (65.6%)    | 0.036     |
| Highest education level attained     | Year 12/below 1 45 (48.4%) | 160 (87.4%)         | 205 (74.3%)    | <0.001    |
|                                      | Above Year 12 2 48 (51.6%) | 23 (12.6%)          | 71 (25.7%)     |           |
| Currently in employment, education   | Yes 81 (87.1%)            | 173 (94.5%)          | 254 (92.0%)    | 0.031     |
| and/or training                      |                           |                      |                |           |
| Socioeconomic status (Index of       |                           |                      |                |           |
| Relative Socioeconomic Disadvantage  |                           |                      |                |           |
| Decile                               |                           |                      |                |           |
| 1                                    | 6 (6.5%)                  | 14 (7.9%)            | 20 (7.4%)      | 0.028     |
| 2                                    | 5 (5.4%)                  | 7 (4.0%)             | 12 (4.4%)      |           |
| 3                                    | 5 (5.4%)                  | 1 (0.6%)             | 6 (2.2%)       |           |
| 4                                    | 8 (8.6%)                  | 11 (6.2%)            | 19 (7.0%)      |           |
| 5                                    | 11 (11.8%)                | 5 (2.8%)             | 16 (5.9%)      |           |
| 6                                    | 9 (9.7%)                  | 18 (10.2%)           | 27 (10.0%)     |           |
| 7                                    | 8 (8.6%)                  | 16 (9.0%)            | 24 (8.9%)      |           |
| 8                                    | 9 (9.7%)                  | 19 (10.7%)           | 28 (10.4%)     |           |
| 9                                    | 12 (12.9%)                | 36 (20.3%)           | 48 (17.8%)     |           |
| 10                                   | 20 (21.5%)                | 50 (28.2%)           | 70 (25.9%)     |           |
| Parents separated/divorced           | Yes 30 (32.3%)            | 36 (19.7%)           | 66 (23.9%)     | 0.024     |
| Has siblings                         | Yes 82 (88.2%)            | 161 (88.0%)          | 243 (88.0%)    | 0.963     |
Table 2. Cont.

| Born in Australia* | Cancer Survivors (n = 93) | Comparison (n = 183) | Total (n = 276) | p-Value |
|-------------------|--------------------------|----------------------|----------------|---------|
| Yes               | 84 (90.3%)               | 128 (69.9%)          | 212 (77.1)     | <0.001  |
| Aboriginal and/or Torres Strait Islander descent | 1 (1.1%) | 3 (1.6%) | 4 (0.7%) | 0.534 |
| LOTE at home **   | 13 (14.0%)               | 93 (50.8%)           | 106 (38.4%)    | <0.001  |

Cancer-related characteristics (survivor group only; n = 93)

| Age at cancer diagnosis (years) | Cancer Survivors | Comparison | Total | p-Value |
|---------------------------------|------------------|------------|-------|---------|
| M = 14.7 (SD = 6.59);           | 51 (54.8%)       | N/A        | N/A   | -       |
| Median = 16.0; IQR = 8.5, Range: 0–27 | N/A          | N/A        | N/A   | -       |

| Time since diagnosis (years) | Cancer Survivors | Comparison | Total | p-Value |
|------------------------------|------------------|------------|-------|---------|
| Median = 3.0; IQR = 11.0, Range: 0–26.6 | 51 (54.8%)       | N/A        | N/A   | -       |

| Cancer diagnosis category | Cancer Survivors | Comparison | Total | p-Value |
|---------------------------|------------------|------------|-------|---------|
| Blood                     | 51 (54.8%)       | N/A        | N/A   | -       |
| Solid tumor               | 29 (31.2%)       | N/A        | N/A   | -       |
| Brain                     | 11 (11.8%)       | N/A        | N/A   | -       |
| Not sure                  | 2 (2.2%)         | N/A        | N/A   | -       |

| Treatments received       | Cancer Survivors | Comparison | Total | p-Value |
|---------------------------|------------------|------------|-------|---------|
| Surgical                  | 51 (54.8%)       | N/A        | N/A   | -       |
| Chemotherapy              | 83 (89.2%)       | N/A        | N/A   | -       |
| Radiotherapy              | 43 (46.2%)       | N/A        | N/A   | -       |
| Bone marrow/stem cell transplant | 19 (20.4%)     | N/A        | N/A   | -       |
| Relapse (ever recurred/relapsed) | 12 (12.9%)     | N/A        | N/A   | -       |
| Time since treatment (months) | Median = 21.5; IQR = 119.25, Range: 1–309 | N/A      | N/A   | -       |

Bold p-values denote statistical significance at the level of p < 0.05. Abbreviations: AYA = adolescent and young adult; M = mean; N/A = not applicable; SD = standard deviation; IQR = interquartile range; LOTE = Language other than English. 1 Within the Australian education system, Year 12 is the final year of high school prior to tertiary education. 2 'Year 12 and above' included all AYAs who had at least completed their higher-school certificate, as well as AYAs who had completed further studies beyond that including undergraduate, postgraduate university studies, and Technical And Further Education (TAFE) qualifications. Higher decile = more socioeconomic disadvantage *. Overall, the three most common countries of birth other than Australia were China (n = 10, 3.6%), New Zealand (n = 6, 2.2%), and England, South Africa, Singapore, Hong Kong, and Indonesia (n = 4, 1.4%). Additionally, of our control group, n = 23 reported that they were not Australian/New Zealand citizens. Of these, n = 4 (2.2%) reported that they were staying in Australia on a permanent residency visa, and n = 19 (10.4%) reported that they were on student visas. This question was not asked of our cancer group. '' The three most common languages spoken at home were Mandarin (n = 21, 7.7%), Cantonese (n = 17, 6.2%), and Vietnamese (n = 10, 3.6%). Cancer categorizations. Blood cancers: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Fanconi’s anemia, Hodgkin’s Lymphoma, and Non-Hodgkin’s Lymphoma; Solid tumors included bone and soft tissue sarcomas, liposarcoma, seminoma, Wilms’ tumor, hepatoblastoma, breast cancer, ovarian cancer, yolk sac tumor, testicular cancer, submandibular mammary carcinoma, fibrolamella hepatocellular carcinoma, clear cell cervical cancer, metastatic neuroendocrine carcinoid tumor of the appendix; neuroblastomas. Brain cancers: medulloblastomas and other brain/central nervous system cancers.

3.2. Healthcare Use (HCU) Outcomes

Table 3 depicts rates of overall HCU, and for medical, mental health, and medication categories for the AYA cancer survivor group relative to the community-based comparison.
group. Table 4 depicts patterns of HCU across these same categories for cancer survivors alone, according to their age at diagnosis and the length of time since completing active cancer treatment.

Table 3. Comparison of overall, medical and mental healthcare use as well as medication use reported between groups over the past six months (n = 276).

|                        | Cancer Survivors (n = 93) | Comparison (n = 183) | $\chi^2$ | p-Value |
|------------------------|---------------------------|----------------------|---------|---------|
| **Overall HCU**        |                           |                      |         |         |
| Total                  | 61 (65.6%)                | 110 (60.1%)          | 0.786   | 0.375   |
| **Hospital-delivered HCU** |                         |                      |         |         |
| Total                  | 29 (31.2%)                | 37 (20.3%)           | 4.074   | 0.044   |
| ED admission           | 23 (24.7%)                | 24 (13.1%)           | 5.889   | 0.015   |
| Hospital admission     | 15 (16.1%)                | 17 (9.3%)            | 2.814   | 0.093   |
| Oncologist/Radiation oncologist | 19 (20.7%)       | N/A                  | N/A     | N/A     |
| **Medical HCU**        |                           |                      |         |         |
| Total                  | 61 (65.6%)                | 86 (47.0%)           | 8.567   | 0.003   |
| GP                     | 32 (34.8%)                | 65 (35.5%)           | 0.015   | 0.904   |
| Nurse in hospital/community | 12 (13.0%)            | N/A                  | N/A     | N/A     |
| Fertility specialist   | 12 (13.0%)                | N/A                  | N/A     | N/A     |
| Other health professionals | 11 (12.0%)          | 14 (7.7%)            | 1.374   | 0.241   |
| **Mental HCU**         |                           |                      |         |         |
| Total                  | 49 (52.7%)                | 43 (23.5%)           | 23.645  | <0.001  |
| Psychologist           | 33 (35.5%)                | 30 (16.4%)           | 12.757  | <0.001  |
| Social worker          | 32 (34.4%)                | 14 (7.7%)            | 31.789  | <0.001  |
| Counsellor             | 18 (19.4%)                | 26 (14.2%)           | 1.219   | 0.270   |
| Psychiatrist           | 10 (10.8%)                | 14 (7.7%)            | 0.748   | 0.387   |
| Community mental health/cancer support organization | 25 (27.2%) | 24 (13.1%) | 8.264 | 0.004 |
| **Reported ≥ 1 medication used** |               |                      |         |         |
| Average number of medications used, M (SD) | 1.7 (2.35) | 0.7 (1.08) | T = 10.622 | <0.001 |

Bold p-values denote statistical significance at the level of p < 0.05. 1 Total hospital-delivered HCU included emergency department, hospital admissions, and oncologist/radiation oncologist service use; 2 total medical HCU included all hospital based HCU as well as GP, nurse, fertility specialist, and ‘other’ health professionals. 3 Several professionals including oncologists were not included in the comparison group survey. Abbreviations: ED = Emergency Department; GP = general practitioner; HCU = healthcare use; M = mean; SD = standard deviation.

### 3.2.1. Overall HCU Patterns of Use (Rates)

Our AYA cancer survivor group reported similar rates of overall HCU as the comparison group over the past six months (65.6% vs. 60.1%; $\chi^2 = 0.786$, $p = 0.375$). Within the cancer survivor group, those diagnosed as an AYA reported higher rates of overall HCU relative to survivors diagnosed at a pediatric age (84.5% vs. 34.3%; $\chi^2 = 24.370$, $p < 0.001$; Table 4). Examined according to time since cancer treatment completion, a clear and significant pattern emerged; AYAs in their first year post-treatment reported the highest overall HCU (90.5%), which declined steadily for survivors in their second (77.8%), third or fourth
(61.5%) or fifth or more years post-treatment (i.e., long-term survivors; 27.6%; $\chi^2 = 30.770$, $p < 0.001$; Table 4).

Table 4. Patterns of healthcare use reported by cancer survivors, according to age at diagnosis and time since treatment ($n = 93$).

| Age at Diagnosis $^a$ | Number of Years Post-Treatment $^b$ | Total HCU | Pediatric ($n = 35$) | AYA ($n = 58$) | $\chi^2$ | $p^*$-Value | 1 ($n = 42$) | 2–4 ($n = 22$) | 5* ($n = 29$) | $\chi^2$ | $p^*$-Value |
|-----------------------|-------------------------------------|-----------|----------------------|----------------|--------|------------|-----------|-------------|-------------|--------|------------|
| Overall               | 12 (34.3%)                          | 49 (84.5%)| 24.370               |                |        | <0.001     | 38 (90.5%)| 15 (68.2%)  | 8 (27.6%)   | 30.770 | <0.001     |
| Hospital-delivered HCU $^1$ |                                    |           |                      |                |        |            |           |             |             |        |             |
| ED admission          | 4 (11.4%)                           | 19 (32.8%)| 5.335                | 14 (33.3%)     |        | 0.021      | 6 (27.3%) | 3 (10.3%)   | 7.383       | 0.061  |
| Hospital admission    | 5 (14.3%)                           | 10 (17.2%)| 0.141                | 10 (23.8%)     |        |            | 4 (13.8%) | 3 (10.3%)   | 4.616       | 0.202  |
| Oncologist/Radiation oncologist $^3$ | 8 (22.9%)                          | 22 (37.9%)| 2.445                | 19 (45.2%)     |        |            | 4 (13.8%) | 3 (10.3%)   | 9.302       | 0.026  |
| Medical HCU $^2$      |                                     |           |                      |                |        |            |           |             |             |        |             |
| GP                    | 13 (37.1%)                          | 19 (32.8%)| 0.139                | 0.710          |        |            | 9 (31.0%) | 9 (31.0%)   | 0.635       | 0.888  |
| Nurse in hospital/community | 2 (5.7%)                           | 17 (29.3%)| 7.692                | 17 (40.5%)     |        | 0.012      | 1 (4.5%)  | 1 (4.5%)    | 19.749      | <0.001 |
| Fertility specialist  | 1 (2.9%)                            | 11 (19.0%)| 5.168                | 0.023          |        |            | 2 (6.9%)  | 2 (6.9%)    | 3.892       | 0.273  |
| Other health professionals | 1 (2.9%)                          | 10 (17.2%)| 4.443                | 0.035          |        |            | 9 (21.4%) | 1 (4.5%)    | 1 (3.4%)    | 7.332  |
| Total                 | 17 (48.6%)                          | 44 (75.9%)| 24.370               |                |        | <0.001     | 33 (78.6%)| 15 (68.2%)  | 13 (44.8%)  | 9.362  | 0.025     |
| GP                    | 13 (37.1%)                          | 19 (32.8%)| 0.139                | 0.710          |        |            | 9 (31.0%) | 9 (31.0%)   | 0.635       | 0.888  |
| Social worker         | 4 (11.4%)                           | 28 (48.3%)| 13.131               |                |        | <0.001     | 25 (59.5%)| 4 (18.2%)   | 26.400      | <0.001 |
| Counsellor            | 2 (5.7%)                            | 16 (27.6%)| 6.690                | 0.010          |        |            | 13 (35.7%)| 1 (4.5%)    | 13.597      | 0.004  |
| Psychiatrist          | 2 (5.7%)                            | 3 (13.8%) | 1.485                | 0.223          |        |            | 6 (14.3%) | 1 (4.5%)    | 2.119       | 0.548  |
| Community mental health/cancer support organization | 3 (8.6%)                          | 22 (38.6%)| 9.878                | 0.002          |        |            | 19 (45.2%)| 5 (22.7%)   | 16.946      | 0.001  |
| Reported ≥ 1 medication used | 21 (60.0%)                         | 36 (62.1%)| 0.039                | 0.843          |        |            | 25 (59.5%)| 15 (68.2%)  | 17 (58.6%)  | 1.174  | 0.759     |
| Average number of medications used—M (SD) | 1.8 (2.29)                         | 1.8 (2.41) | t = −0.303          | 0.763          |        |            | 1.8 (2.29)| 1.8 (2.68)  | 1.7 (2.26)  |

Bold $p$-values denote statistical significance at the level of $p < 0.05$. $^a$ Age at diagnosis: pediatric = diagnosed <15 years; AYA = 15 years and above. $^b$ Years post-treatment completion: 1st year, 0–12 months ago, inclusive; 2nd year–4th years post-treatment: 13–59 months inclusive; 5th year post-treatment: ≥60 months post-treatment. $^1$ Total hospital-delivered HCU included emergency department, hospital admissions, and oncologist/radiation oncologist service use; $^2$ total medical HCU included all hospital based HCU as well as GP, nurse, fertility specialist, and ‘other’ health professionals. $^3$ Several professionals including oncologists were not included in the comparison group survey. Abbreviations: AYA = adolescent and young adult; ED = Emergency Department; GP = general practitioner; HCU = healthcare use; M = mean; SD = standard deviation. $t$-test statistic.
Factors Associated with HCU among Cancer Survivors

Access (any use): Table 5 depicts univariable and multivariable regressions accounting for all HCU outcomes within the cancer survivor group. Multivariable analyses indicated that survivors who were younger at diagnosis ($OR = 0.72; CI = 0.55–0.96; p = 0.023$), were diagnosed with a non-blood cancer ($OR = 9.79; CI = 1.48–64.87; p = 0.018$) and had completed treatment more recently ($OR = 0.95; CI = 0.92–0.98; p < 0.001$) were more likely to report accessing any type of HCU. These findings indicated that the likelihood of survivors reporting recent HCU decreased as both survivors’ age at diagnosis and time since treatment completion increased ($p < 0.001$) and suggested that survivors of non-blood cancers (mostly solid and brain tumors) were more likely than survivors of blood cancers to report HCU in the past six months.

### Table 5. Summary of univariable and multivariable regressions predicting likelihood of total healthcare use (HCU), and in medical, mental health, and medication domains among cancer survivors ($n = 93$).

|                                      | Univariable Regression | Multivariable Regression |
|--------------------------------------|------------------------|--------------------------|
|                                      | OR                     | 95% CI                   | $p$-Value | OR                     | 95% CI                   | $p$-Value | R Square |
|                                      |                        |                          |           |                        |                          |           |          |
| **Total HCU**                        |                        |                          |           |                        |                          |           |          |
| Sociodemographic predictors          |                        |                          |           |                        |                          |           |          |
| Sex (female vs. male)                | 0.99                   | 0.41–2.32                | 0.962     | 1.57                   | 0.34–7.23                | 0.563     | 0.503 $^a$/0.696 $^b$ |
| Employment status                    | 0.15                   | 0.02–1.19                | 0.073     | 0.27                   | 0.02–3.53                | 0.315     |          |
|                                      |                        |                          |           |                        |                          |           |          |
| Cancer-related predictors            |                        |                          |           |                        |                          |           |          |
| Age at diagnosis (in years)          | 1.21                   | 1.11–1.32                | $<0.001$  | 0.72                   | 0.55–0.96                | 0.023     |          |
| Diagnosis (non-blood vs. blood cancers) | 1.16                   | 0.49–2.76                | 0.737     | 9.79                   | 1.48–64.87               | 0.018     |          |
| Time since treatment (per month)     | 0.98                   | 0.97–0.99                | $<0.001$  | 0.95                   | 0.92–0.98                | $<0.001$  |          |
|                                      |                        |                          |           |                        |                          |           |          |
| **Medical HCU**                      |                        |                          |           |                        |                          |           |          |
| Sociodemographic predictors          |                        |                          |           |                        |                          |           |          |
| Sex (female vs. male)                | 2.12                   | 0.89–5.07                | 0.089     | 4.38                   | 1.42–13.58               | 0.010     | 0.219 $^a$/0.305 $^b$ |
| Employment status                    | 0.15                   | 0.02–1.19                | 0.073     | 0.11                   | 0.01–1.19                | 0.069     |          |
|                                      |                        |                          |           |                        |                          |           |          |
| Cancer-related predictors            |                        |                          |           |                        |                          |           |          |
| Age at diagnosis (in years)          | 1.11                   | 1.04–1.19                | $0.003$   | 1.10                   | 0.91–1.32                | 0.321     |          |
| Diagnosis (non-blood vs. blood cancers) | 0.96                   | 0.40–2.27                | 0.917     | 1.72                   | 0.57–5.16                | 0.333     |          |
| Time since treatment (per month)     | 0.99                   | 0.99–0.99                | $0.003$   | 1.00                   | 0.99–1.01                | $0.825$   |          |
|                                      |                        |                          |           |                        |                          |           |          |
| **Mental HCU**                       |                        |                          |           |                        |                          |           |          |

---

$^a$ Adjusted for age at diagnosis and diagnosis.

$^b$ Adjusted for age at diagnosis, diagnosis, and time since treatment.
Table 5. Cont.

|                                | Univariable Regression | Multivariable Regression |
|--------------------------------|------------------------|--------------------------|
|                                | OR   | 95%CI | p-Value | OR   | 95%CI | p-Value | R Square |
| Sociodemographic predictors    |      |      |         |      |      |         |          |
| Sex (female vs. male)          | 0.93 | 0.41–2.12 | 0.868 | 0.97 | 0.36–2.61 | 0.958 | 0.186 \(^a\)/0.248 \(^b\) |
| Employment status (working/studying vs. not) | 0.77 | 0.23–2.63 | 0.675 | 0.93 | 0.21–4.06 | 0.920 |
| Speaks a language other than English at home | 1.06 | −0.33–3.42 | 0.928 | 1.03 | 0.26–4.11 | 0.970 |
| Cancer-related predictors      |      |      |         |      |      |         |          |
| Age at diagnosis (in years)    | 1.12 | 1.04–1.20 | 0.002 | 0.95 | 0.81–1.12 | 0.573 |
| Diagnosis (non-blood vs. blood cancers) | 1.68 | 0.73–3.86 | 0.221 | 3.24 | 1.12–9.35 | 0.030 |
| Time since treatment (per month) | 0.99 | 0.99–1.00 | 0.002 | 0.99 | 0.97–1.00 | 0.056 |
| Medication use \(^1\)          |      |      |         |      |      |         |          |
| Sex (female vs. male)          | 0.49 | 0.21–1.12 | 0.092 | 0.57 | 0.24–1.39 | 0.219 | 0.046 \(^a\)/0.062 \(^b\) |
| Employment status (working/studying vs. not) | 1.19 | 0.35–4.00 | 0.780 | 0.77 | 0.20–2.97 | 0.703 |
| Speaks a language other than English at home | 0.49 | 0.15–1.62 | 0.239 | 0.70 | 0.19–2.58 | 0.596 |
| Age at diagnosis (in years)    | 1.02 | 0.96–1.08 | 0.576 | 1.07 | 0.94–1.22 | 0.321 |
| Diagnosis (non-blood vs. blood cancers) | 1.09 | 0.48–2.49 | 0.832 | 1.31 | 0.53–3.20 | 0.561 |
| Time since treatment (per month) | 1.00 | 1.00–1.01 | 0.726 | 1.00 | 0.99–1.01 | 0.358 |

Bold p-values denote statistical significance at the level of p < 0.05. \(^1\) Medication use excluding medication-based contraceptives, as this was only reported by females. \(^a\) Cox and Snell R\(^2\); \(^b\) Nagelkerke R\(^2\) Abbreviations: CI = confidence interval; OR = odds ratio.

3.2.2. Medical HCU
Patterns of Use (Rates)

Our cancer survivor group reported higher rates of medical HCU than our comparison group in the last six months (66% versus 47%; p = 0.003). The two groups reported engaging with GP services at similar rates, with approximately one-third of each group reporting a GP visit during the past six months (p = 0.904; Table 3). Survivors reported higher rates of hospital-delivered HCU (31%) relative to comparisons (20%; \(\chi^2 = 4.074\); p = 0.044), including emergency department presentations (25% versus 13%; \(\chi^2 = 5.889\); p = 0.015; Table 3).

AYA cancer survivors who had been diagnosed at an AYA age reported higher rates of medical HCU overall compared with survivors diagnosed at a pediatric age (75.9% vs. 48.6%; \(\chi^2 = 24.370\); p < 0.001; Table 4). This same pattern emerged for AYAs’ recent consultations with nurses, fertility specialists, and other health professionals, though not for GPs (see Table 4). Survivors diagnosed as AYAs also reported more recent emergency department admissions relative to survivors diagnosed at a younger age (32.8% vs. 11.4%; \(\chi^2 = 5.335\); p = 0.021; Table 4).

Examined according to time since treatment completion, AYAs who had completed treatment most recently were more likely to report having accessed any medical HCU overall (\(\chi^2 = 9.362\); p = 0.025; Table 4) as well as having seen their oncologist in the past six
months, relative survivors diagnosed further ago ($\chi^2 = 9.302, p = 0.026; \text{Table 4}$). Almost half of survivors who were within their first year post-treatment reported having seen their oncologist in the past six months (45.2%), a rate that steadily declined with each year post-treatment, reaching 13.8% for survivors beyond five years post-treatment (Table 4). AYAs in their first-year post-treatment were most likely to report having seen a nurse recently (40.5%), a rate that sharply declined for all subsequent years post-treatment (to 3.4% at 5 years post-treatment; $\chi^2 = 19.749; p < 0.001$). A similar proportion of survivors reported having seen a GP recently, regardless of time post-treatment (ranging from 31.0 to 44.4% across all years post-treatment), which did not significantly differ with greater time since treatment ($\chi^2 = 0.0635, p = 0.888$).

Factors Associated with HCU among Cancer Survivors

Access (any use):Within adjusted multivariable analyses, female survivors were more likely than their male counterparts to report accessing medical HCU during the past six months (OR = 4.38; CI = 1.42–13.58; $p = 0.010; \text{Table 6}$). No other sociodemographic or cancer-related factors were associated with access to medical HCU.

| Table 6. Multivariable Poisson regressions predicting the total number of types of HCU cancer survivors accessed within each category. |
|---|---|---|---|
| RR | 95% CI RR | Wald $\chi^2$ | $p$ |
| Total HCU | | | |
| Sex (female vs. male) | 1.06 | 0.71, 1.58 | 0.09 | 0.763 |
| Employment status (working/studying vs. not) | 0.76 | 0.45, 1.28 | 1.06 | 0.304 |
| English spoken at home vs. not | 1.49 | 0.89, 2.49 | 2.33 | 0.127 |
| Cancer-related predictors | | | |
| Age at diagnosis (in years) | 0.99 | 0.93, 1.05 | 0.20 | 0.651 |
| Diagnosis (non-blood vs. blood cancers) | 1.27 | 0.86, 1.87 | 1.43 | 0.232 |
| Time since treatment (per month) | 0.99 | 0.99, 1.00 | 9.71 | 0.002 |
| Hospital-delivered HCU | | | |
| Sex (female vs. male) | 1.58 | 0.98, 2.55 | 3.53 | 0.060 |
| Employment status (working/studying vs. not) | 0.77 | 0.43, 1.39 | 0.74 | 0.389 |
| English spoken at home vs. not | 0.93 | 0.46, 1.86 | 0.05 | 0.832 |
| Cancer-related predictors | | | |
| Age at diagnosis (in years) | 0.98 | 0.92, 1.05 | 0.29 | 0.590 |
| Diagnosis (non-blood vs. blood cancers) | 1.21 | 0.78, 1.90 | 0.71 | 0.401 |
| Time since treatment (per month) | 0.99 | 0.98, 0.99 | 7.94 | 0.005 |
| Medical HCU | | | |
| Sex (female vs. male) | 1.47 | 0.97, 2.23 | 3.29 | 0.070 |
| Employment status (working/studying vs. not) | 0.65 | 0.39, 1.08 | 2.74 | 0.098 |
| English spoken at home vs. not | 1.36 | 0.79, 2.36 | 1.23 | 0.268 |
Table 6. Cont.

| RR   | 95%CI RR | Wald | p    |
|------|----------|------|------|
| Age at diagnosis (in years) | 0.98    | 0.93, 1.04 | 0.32 | 0.570 |
| Diagnosis (non-blood vs. blood cancers) | 1.06    | 0.71, 1.59 | 0.09 | 0.770 |
| Time since treatment (per month) | 0.99    | 0.98, 0.99 | 7.19 | 0.007 |
| Sex (female vs. male) | 1.11    | 0.70, 1.75 | 0.20 | 0.652 |
| Employment status (working/studying vs. not) | 0.88    | 0.47, 1.65 | 0.15 | 0.697 |
| English spoken at home vs. not | 1.26    | 0.69, 2.32 | 0.57 | 0.450 |
| Age at diagnosis (in years) | 0.98    | 0.92, 1.05 | 0.27 | 0.607 |
| Diagnosis (non-blood vs. blood cancers) | 1.38    | 0.89, 2.16 | 2.06 | 0.151 |
| Time since treatment (per month) | 0.99    | 0.98, 0.99 | 7.41 | 0.006 |
| Medication use | 3.06    |      | 0.802 |
| Sex (female vs. male) | 1.40    | 0.73, 2.68 | 1.01 | 0.316 |
| Employment status (working/studying vs. not) | 1.07    | 0.40, 2.82 | 0.02 | 0.899 |
| English spoken at home vs. not | 0.76    | 0.27, 2.17 | 0.26 | 0.613 |
| Age at diagnosis (in years) | 1.05    | 0.96, 1.14 | 1.02 | 0.311 |
| Diagnosis (non-blood vs. blood cancers) | 1.01    | 0.54, 1.88 | 0.00 | 0.981 |
| Time since treatment (per month) | 1.00    | 1.00, 1.01 | 0.43 | 0.514 |

Bold p-values denote statistical significance at the level of p < 0.05. Abbreviations: CI = confidence interval; HCU = healthcare use; RR = relative rate of use.

Intensity of usage (number of types): Time since treatment was the only factor associated with greater HCU; survivors who had completed treatment more recently reported greater HCU overall ($\chi^2 = 9.707, p = 0.002$; Table 6), as well as specifically within medical HCU ($\chi^2 = 7.189, p = 0.007$) and hospital-delivered HCU ($\chi^2 = 7.942, p = 0.005$).

3.2.3. Mental Health, and Mental HCU

Depression, Anxiety, and Perceived Health

A minority of all participants reported moderate or greater levels of depression and/or anxiety during the past week ($n = 44/276$, 15.9%). Our cancer survivor group had lower average depression and anxiety scores than the comparison group (p-values $\leq 0.003$, Table 7). Furthermore, survivors were less likely than those in the comparison group to report current anxiety symptoms in the moderate-to-severe range (OR = 0.31, 95%CI = 0.10–0.93, $p = 0.037$). The groups did not differ on their self-assessed current health-related quality of life, indicating similar perceptions of satisfaction with their overall health ($\chi^2 = 1.30, p = 0.255$; Table 7).
Table 7. Mental health, perceived health-related quality of life, and general functioning outcomes across groups.

| Health-related quality of life | Cancer Survivors \((n = 93)\) | Comparison \((n = 183)\) | Total \((n = 276)\) | \(p\)-Value |
|-------------------------------|---------------------------------|---------------------------|-------------------|-------------|
| Good/very good/excellent      | 37 (39.8%)                      | 86 (47.0%)                | 123 (44.6%)       | 0.255       |
| Poor/fair                     | 56 (60.2%)                      | 97 (53.0%)                | 153 (55.4%)       |             |
| Overall anxiety level \(^1\) (DASS-21) |                                 |                           |                   |             |
| Normal                        | 79 (84.9%)                      | 139 (76.0%)               | 218 (79.0%)       |             |
| Mild                          | 10 (10.8%)                      | 23 (12.6%)                | 33 (12.0%)        |             |
| Moderate                      | 4 (4.3%)                        | 15 (8.2%)                 | 19 (6.9%)         |             |
| Severe                        | 0 (0.0%)                        | 6 (3.3%)                  | 6 (2.2%)          |             |
| Total scores \(M (SD)\)       | 4.8 (5.7)                       | 7.9 (7.5)                 | 6.8 (7.1)         | 0.001       |
| Overall depression level \(^1\) (DASS-21) |                                 |                           |                   |             |
| Normal                        | 75 (80.6%)                      | 130 (71.4%)               | 205 (74.5%)       |             |
| Mild                          | 9 (9.7%)                        | 29 (15.9%)                | 38 (13.8%)        |             |
| Moderate                      | 7 (7.5%)                        | 19 (10.4%)                | 26 (9.5%)         |             |
| Severe                        | 2 (2.2%)                        | 2 (1.1%)                  | 4 (1.5%)          |             |
| Extremely severe              | 0 (0.0%)                        | 2 (1.1%)                  | 2 (0.7%)          |             |
| Total scores \(M (SD)\)       | 5.9 (7.5)                       | 9.0 (8.0)                 | 7.9 (8.0)         | 0.003       |
| Overall missed study/work \(^2\) |                                 |                           |                   |             |
| Took days off work/study—N (%) | 45 (47.3%)                      | 92 (54.1%)                | 137 (49.6%)       | 0.767       |
| Total days absent \(M (SD)\)  | 3.1 (6.6)                       | 2.2 (4.1)                 | 2.5 (5.1)         | 0.910       |
| Reasons for missed study/work \(^2\) |                                 |                           |                   |             |
| Sickness or feeling unwell    | 25 (56.8%)                      | 43 (43.4%)                | 68 (47.2%)        | 0.117       |
| Tiredness or low energy       | 8 (18.2%)                       | 37 (37.4%)                | 45 (31.5%)        | 0.023       |
| Low motivation or ‘feeling flat’ | 3 (6.8%)                       | 19 (19.2%)                | 22 (15.4%)        | 0.058       |
| Medical or health-related appointments | 2 (4.5%)                       | 4 (4.0%)                  | 6 (4.2%)          | 0.889       |
| Unable to keep up with the workload | 16 (36.4%)                      | 54 (54.5%)                | 70 (49.0%)        | 0.045       |
| Self-conscious about physical scars or changes | 18 (40.9%)                      | 9 (9.1%)                  | 27 (18.9%)        | <0.001      |
| Difficulty in getting on with friends/colleagues | 2 (4.5%)                       | 10 (10.1%)                | 12 (8.4%)         | 0.269       |
| Others                        | 5 (11.4%)                       | 11 (11.1%)                | 16 (11.2%)        | 0.965       |
| Days engaged in activities \(M (SD)\) | 15.0 (6.3)                      | 12.4 (5.6)                | 13.3 (5.9)        | 0.001       |
Table 7. Cont.

| Number of AYAs engaged in different activities | Cancer Survivors (n = 93) | Comparison (n = 183) | Total (n = 276) | p-Value |
|-----------------------------------------------|--------------------------|---------------------|----------------|---------|
| Paid work                                     | 55 (59.1%)               | 110 (60.1%)         | 165 (59.8%)    | 0.897   |
| Study                                         | 46 (49.5%)               | 162 (88.5%)         | 208 (75.4%)    | <0.001  |
| Exercise or sports                            | 79 (84.9%)               | 134 (73.2%)         | 213 (77.2%)    | 0.028   |
| Personal hobbies                              | 84 (90.3%)               | 137 (74.9%)         | 221 (80.1%)    | 0.002   |
| Socializing with friends                      | 85 (91.4%)               | 156 (85.2%)         | 241 (87.3%)    | 0.147   |
| Socializing with peers with cancer            | 20 (21.5%)               | N/A                 | N/A            | -       |
| Days of engagement: by activity               |                          |                     |                |         |
| Paid work                                     | 14.6 (7.4)               | 9.9 (6.4)           | 11.5 (7.1)     | <0.001  |
| Study                                         | 13.6 (7.9)               | 11.3 (6.6)          | 11.8 (7.0)     | 0.094   |
| Exercise or sports                            | 11.4 (8.1)               | 10.4 (7.3)          | 10.7 (7.6)     | 0.445   |
| Personal hobbies                              | 17.1 (9.8)               | 14.1 (8.9)          | 15.2 (9.3)     | 0.027   |
| Socializing with friends                      | 19.1 (9.5)               | 17.2 (9.6)          | 17.8 (9.6)     | 0.130   |
| Socializing with cancer peers                 | 5.8 (7.0)                | N/A                 | N/A            | -       |

| Participated in group social activities       | N (%)                    |                     |                |         |
| Paid work                                     | 42 (45.2%)               | 114 (62.3%)         | 156 (56.5%)    | 0.007   |

Bold p-values denote statistical significance at the level of p < 0.05. 1 The majority (8/10) of cancer survivor AYAs with higher-range (moderate-extremely severe) DASS-21 scores were within the first five years post-diagnosis. 2 Reasons for missed study/work calculated based on the denominator of AYAs who indicated that they had taken any days off work/study. 3 Socializing included connecting online, e.g., via social media. 4 AYAs with a cancer history were also asked about socializing specifically with other young people with cancer (including connecting online). Abbreviations: AYA = adolescent and young adult; M = mean; SD = standard deviation; DASS-21 = Depression, Anxiety, Stress Scales-Short Form.

Missed Study/Work and Productivity

Approximately half of both groups reported having taken at least some time off from paid work or study in the past month, and the estimated days of missed study/work (time off) was comparable across groups (Table 7). The nominated reasons for these absences differed between groups. The probability of those in the survivor group attributing time taken off from work or study due to ‘self-consciousness and concerns about physical scars’ was higher than in the comparison group (p < 0.001). By contrast, the probability of those in the comparison group attributing their time taken off from work/study as being due to ‘tiredness or low energy’ (p = 0.023) and/or feeling ‘unable to keep up with the workload’ (p = 0.045) was higher than in the survivor group.

Overall, the survivor group also reported engaging in productive activities across more days during the past month than the comparison group (M = 15, SD = 6.3 vs. M = 12.4, SD = 5.6 days; p < 0.001; Table 7). The focus of these activities appeared to differ between groups. Survivors reported relatively greater engagement in personal hobbies (p = 0.002), and exercise/sports (p = 0.028) than the comparison group. By contrast, the comparison group reported more time spent engaging in study (p < 0.001), and group social activities, including activities such as team sports, university/college-run clubs and societies, and youth groups (including religious groups) than the cancer survivor group (p = 0.007).

Patterns of Use (Rates)

A higher proportion of our AYA cancer survivors reported using mental health services than our comparison group (52.7% compared with 23.5%; p < 0.001; Table 3). Within the
cancer survivor group, survivors reported the highest rates of overall mental HCU in their first year post-treatment (73.8%) which declined over all subsequent years post-treatment (to 27.6% beyond 5 years post-diagnosis; $\chi^2 = 18.058, p < 0.001$; see Table 4). A similar pattern emerged for our survivors’ use over time for psychologists ($\chi^2=10.346, p = 0.016$), social workers ($\chi^2 = 26.400, p < 0.001$), counsellors ($\chi^2 = 13.597, p = 0.004$), and community-delivered support organizations ($\chi^2 = 16.946, p < 0.001$; see Table 4). A small proportion of survivors reported engaging with psychiatrists, and this did not differ according to time since completion of treatment ($\chi^2 = 2.119, p = 0.548$).

Supplementary Table S1 details overall mental HCU, and mental HCU according to service/discipline type, according to participant group and distress level. Across cancer survivor and comparison groups, AYAs whose DASS-21 scores were in the higher range (moderate to extremely severe symptom severity) were more likely to report accessing any mental HCU during the past six months relative to less distressed AYAs ($\chi^2 = 10.599, p = 0.001$). Yet, less than half of these distressed AYAs had not accessed any mental healthcare during the past six months (45.5%; Supplementary Table S1). While more distressed AYAs appeared more likely to report mental HCU, the specific type of mental HCU they accessed did not appear to differ as a function of their distress levels; across both cancer survivor and comparison groups, AYAs with greater and lesser distress reported having seen psychologists ($\chi^2 = 2.403, p = 0.169$), psychiatrists ($\chi^2 = 0.469, p = 0.557$), social workers ($\chi^2 = 0.022, p = 0.883$), counselors ($\chi^2 = 0.795, p = 0.372$) and GPs ($\chi^2 = 1.435, p = 0.231$) at similar rates during the past six months.

Factors Associated with Mental HCU among Cancer Survivors

Access (any use): Within adjusted multivariable analyses, only cancer diagnosis appeared to account for whether or not survivors reported mental HCU (Table 5). Relative to survivors of blood cancers, survivors of non-blood cancers were more likely to report mental HCU in the last six months ($p = 0.030$).

Intensity of usage (number of types): The Poisson regression analysis revealed that only time since treatment completion significantly accounted for intensity of mental HCU during the past six months. Survivors who had completed treatment more recently reported having accessed more types of mental HCU ($\chi^2 = 7.407, p = 0.006$; Table 6).

3.2.4. Medication Use

Patterns of Use (Rates)

Those in our survivor group were more likely to self-report using at least one medication during the past six months relative to our comparison AYAs ($p = 0.003$) and reported taking a higher number of medications on average over this period ($M = 1.8$ versus $0.7, p < 0.001$, Table 3). A range of medications were described (see Table 8). Vitamins and supplements were the most commonly reported category identified across both groups (reported by 18.3% of survivors and 16.9% of comparison AYAs). Survivors reported higher rates of using psychotropic anti-depressant/anxiety medications (11.8% vs. 5.5%) and pain medications (7.5% vs. 1.1%) relative to the comparison group, including opioid or opioid-like analgesics such as endone, oxycodone, and tramadol hydrochloride. A subset of both groups, all of whom were female, reported using medication-based contraceptives (19.2% of female survivors, 16.9% of female comparison AYAs). The small cell numbers in these data prohibited a more granular statistical analysis of specific medications.

When psychotropic medications were examined, across both groups, AYAs who reported having ever seen a psychologist, psychiatrist, or counselor at any time in the past (prior to study intake) were more likely to report having used psychotropic medications during the past six months ($F = 12.991, p < 0.001$). We also examined the relationship between AYAs’ current distress levels and their use of psychotropic medications. AYAs who reported DASS-21 depression and/or anxiety scores in a moderate or higher range were more likely to report also using psychotropic medications during the past six months ($\chi^2 = 12.287, p < 0.0001$) than AYAs reporting low anxiety and/or depression scores.
Table 8. Types of medication used in the past six months, by group.

|                                      | Cancer Survivors (n = 93) | Comparison (n = 183) | Total (n = 276) |
|--------------------------------------|---------------------------|----------------------|-----------------|
| Any medication ¹                     | 57                        | 61.3%                | 77              | 42.1% | 134 | 48.6% |
| Vitamins and supplements             | 17                        | 18.3%                | 31              | 16.9% | 48  | 17.4% |
| Anti-depressants/anxiety             | 11                        | 11.8%                | 10              | 5.5%  | 21  | 7.6%  |
| Contraceptive ²                      | 10                        | 19.2%                | 23              | 16.9% | 33  | 18.1% |
| Hormone therapy                      | 9                         | 9.7%                 | 4               | 2.2%  | 13  | 4.7%  |
| Pain killer                          | 7                         | 7.5%                 | 2               | 1.1%  | 9   | 3.3%  |
| Cancer treatment-related medications ³| 5                         | 5.4%                 | 0               | 0.0%  | 5   | 1.8%  |
| Asthma                               | 4                         | 4.3%                 | 3               | 1.6%  | 7   | 2.5%  |
| Steroids                             | 4                         | 4.3%                 | 0               | 0.0%  | 4   | 1.4%  |
| Antibiotics ⁴                        | 4                         | 4.3%                 | 7               | 3.8%  | 11  | 4.0%  |
| Anti-reflux                           | 3                         | 3.2%                 | 2               | 1.1%  | 5   | 1.8%  |
| Insomnia                             | 3                         | 3.2%                 | 8               | 4.4%  | 11  | 4.0%  |
| ADHD                                 | 2                         | 2.2%                 | 4               | 2.2%  | 6   | 2.2%  |
| Anti-seizure                         | 2                         | 2.2%                 | 0               | 0.0%  | 2   | 0.7%  |
| Anti-fungal                          | 2                         | 2.2%                 | 0               | 0.0%  | 2   | 0.7%  |
| Dyslipidemic agents                  | 2                         | 2.2%                 | 0               | 0.0%  | 2   | 0.7%  |
| Antihypertension                     | 1                         | 1.1%                 | 2               | 1.1%  | 3   | 1.1%  |
| Constipation                         | 1                         | 1.1%                 | 0               | 0.0%  | 1   | 0.4%  |
| Anti-histamine                       | 1                         | 1.1%                 | 3               | 1.6%  | 4   | 1.4%  |

Note. ¹ Number reporting at least one medication of any kind. ² Medication-based contraceptive use was calculated as a proportion of female participants within each group as no male respondents reported this, which was n = 52 female cancer survivors and n = 130 female comparison AYAs, respectively. ³ Due to the broad period of survivorship our study captured, a small number of our survivors (5.4%) continued to take medications related to their cancer treatment, including related to leukemia maintenance treatment (e.g., methotrexate), or prophylactic treatment for graft-versus-host disease (e.g., cyclosporine). ⁴ Antibiotics are commonly prescribed for survivors across the first six months following active treatment completion. Abbreviations: ADHD = Attention Deficit and Hyperactivity Disorder.

We also examined the extent to which patterns of psychotropic medication use occurred in conjunction with other forms of mental HCU (Supplementary Table S2). Across the whole sample, AYAs who reported taking some form of psychotropic medication during the past six months were also more likely to report having seen either a psychiatrist or GP during this time (χ² = 22.758, p < 0.001). Three AYA survivors (3/21; 14.3%) using psychotropic medication did not report either having seen a psychiatrist or a GP during this same period in the last six months.

Among the survivor group only, neither AYAs’ age at diagnosis (t = −0.303, p = 0.763) nor their length of time since treatment completion (χ² = 1.174, p = 0.759) appeared to impact their likelihood of reporting recent medication use (Table 4).

Predictors of Use among Cancer Survivors

Access (any use): Across univariable and multivariable analyses, no variables appeared to be associated with survivors’ likelihood of reporting recent medication use (when medical contraceptive use was excluded; Table 6).

Intensity of usage (number of types): No sociodemographic or cancer/treatment-related factors were significantly associated with the number of medications survivors
reported taking. AYAs’ length of time into survivorship did not significantly impact the rates at which they reported using any medications, with early- and longer-term survivors reporting this at similar rates ($\chi^2 = 1.174, p = 0.759$; Table 4).

3.2.5. Relationship between Greater HCU, Health-Related Quality of Life and General Functioning among AYA Cancer Survivors

Engagement with HCU and Perceived Health-Related Quality of Life Status

Taken together, AYA survivors’ recent degree of engagement in overall HCU and their cancer diagnosis type were both independently associated with their perceived health-related quality of life. Poorer perceived health-related quality of life was associated with fewer reported types of recent HCU ($t = -2.558, p = 0.012$) and a blood cancer diagnosis ($t = -2.078, p = 0.041$; Supplementary Table S3).

Relationship between HCU and Missed Study/Work and Productivity

Adjusted multivariable analyses revealed that the extent to which survivors had accessed different types of HCU recently, together with participant sex, was associated with engagement with work/study (Supplementary Table S3): more days engaged in work/study were observed among female AYA survivors ($t = 2.252, p = 0.027$) and those who reported accessing fewer types of HCU recently ($t = -2.256, p = 0.027$).

4. Discussion

At the completion of cancer treatment, it is important that AYA cancer survivors have the best possible opportunity to rejoin their peers on the developmental trajectory towards independent, well-functioning adults. Understanding how AYAs continue to use the healthcare system to assist them on this path plays an important role in optimizing survivors’ medical and psychological well-being in the years after cancer has been successfully treated. Relative to a community-based comparison group, our cohort of AYA survivors reported higher total HCU, including greater medical and mental HCU, which was especially prominent in the first few years after completing active cancer treatment. They accessed specialist and hospital-delivered services more often than GPs. These young survivors were more likely than those in our comparison group to have recently engaged with mental health services, and to be taking more medication. Our survivors also appeared to be functioning well. On average, they were less distressed than the comparison subjects, with similar rates of participation in work or study and higher engagement with hobbies, sports and group social activities. Although the comparison group was drawn from a non-matched convenience sample, these data may indicate that our survivor sample had recovered somewhat from the cancer-related educational and vocational goal disruption that has been linked to poorer mental health and quality of life long-term [2,47,48].

Across analyses, several factors repeatedly emerged as being associated with greater HCU among survivors: more recent treatment completion, female sex, and being diagnosed with a non-blood cancer (i.e., brain or solid tumor). Our finding that HCU decreased as the time since treatment increased echoes previous research [26,49–52]. Given that survivors are at increased risk of late effects the further from treatment they are [50], the reduced HCU during this period may represent a significant gap in care. Further, unlike in other countries such as the United States (US), in Australia hospital-delivered services are largely free of financial cost for survivors; this means that in contrast to US data [33], cost may not have been a considerable barrier for the hospital-delivered, medical HCU at least. Brain and solid tumor survivors, and female survivors, were groups who continued to access medical and mental HCU to a greater extent into survivorship. This may indicate that healthcare services may need to devote particular efforts to continue to effectively engage male survivors, as well as survivors of blood cancers, over time.

Echoing other recent research [26], our study is unable to determine the extent to which the medical or mental HCU accessed in survivorship was appropriate. The finding that females had accessed more care raises questions around whether those accessing services
are those who need it most. Previous studies have reported that male AYA cancer survivors are more likely to experience higher levels of unmet information needs [53,54], and yet are significantly less likely to access medical care into long-term survivorship [49,52]. Pleasingly, we found that AYAs who were currently more distressed had engaged with mental HCU to a greater degree. We also found that among our survivors, greater overall HCU was associated with better self-reported health-related quality of life. These patterns mirror several other studies [26,55,56]. While our cross-sectional data cannot determine causality, this pattern may indicate that the healthcare being accessed was to some extent achieving its goals: that is, that AYAs’ recent HCU was facilitating improved perceived health overall, with mental healthcare targeted towards, and accessed by, individuals currently distressed and in need of healthcare.

The higher utilization of mental healthcare services by our AYA survivor cohort relative to our comparison group may have contributed to their lower self-reported distress. In Australia, data highlight a considerable gap in mental healthcare for AYAs with mental health problems in the general community: while approximately 25% access some form of treatment, fewer than 2% receive specific help from mental health specialists [57]. Encouragingly, our data appeared to show less evidence of a mental health treatment gap among our survivor group relative to comparison AYAs: survivors’ mental HCU appeared to be relatively well matched with their distress levels, as a greater proportion of highly-distressed AYA survivors reported mental HCU relative to less distressed AYAs. By contrast, over half of the high-distressed comparison AYAs reported no mental HCU in the past six months. This was the case across several disciplines of mental health professionals, including social work and psychology. It may be that our survivor group benefited from greater access to hospital-delivered, cost-free psychology and social work services into survivorship [30,58].

The finding that our survivor group showed particularly high rates of mental HCU in the early few years post-treatment, which decreased with time, may also indicate that hospital-delivered services were serving as critical gateways to, and/or providers of, comprehensive screening and referral to age-appropriate mental health interventions. Our survivor group also reported greater use of support organizations in the community, some of which offer counselling services and may also have addressed these mental health needs. These findings stand in contrast to reports of a lack of access to age-appropriate, mental health services available to AYAs without cancer in the state of New South Wales [59].

In this study, psychotropic medication usage seemed to be relatively well aligned with anxiety and depression scores in our survivor sample, in contrast to a substantial gap between the two in the comparison sample. Despite our survivors’ overall positive general functioning outcomes and lower distress, almost 12% of them reported currently taking anti-depressant and/or anti-anxiety medications, double the rate in our comparison group (5.5%). This rate was somewhat lower than recent US data showing that 22% of long-term childhood cancer survivors reported currently using psychotropic medications however [60]. Prior research has highlighted that AYA cancer survivors may take antidepressant medications at rates 20–38% higher than their peers [61,62]. Considering our survivor cohort’s relatively lower distress, it may be that this cohort of survivors was somewhat ‘over-prescribed’, or that prescription use has lingered without being monitored or adjusted. It may also reflect gaps in accessing pharmacological treatment in the community comparison group however. Pharmacological treatments for mental health disorders are indicated at the higher end of distress, after other treatments have been pursued (e.g., psychological ‘talking therapies’ such as cognitive-behavioral therapy) [63]. It is possible that for these survivors, the pharmacological treatment had effectively treated their symptoms, but had not yet been reduced or weaned. That a minority of our survivor cohort were taking psychotropic medications without concurrent engagement in psychological talking therapies is contrary to recommendations within guideline-driven care, and highlights opportunities for improving clinical care.
Finally, our data also highlighted that vitamins/supplements were the most commonly-reported ‘medication’ type across both survivor and comparison-group AYAs. This is consistent with recent research which found 42% of cancer survivors ranging from childhood to young adulthood reported using non-pharmacological or natural therapies, such as herb/supplement mixtures [64]. While some of this use may be appropriate and indicated (e.g., zinc in the case of vitamin deficiency), some may not, and may be not evidence-based. Our data cannot reveal the motivations behind this use. While it may reflect a more holistic orientation to ‘wellness’, greater use of complementary and alternative medicines can also reflect ongoing health-related concerns, such as higher fear of cancer recurrence [65]. Given their relative cost, understanding the extent of, and motivations for, vitamin/supplement use in young cancer survivors is an important point for future research.

4.1. Strengths and Limitations

This paper is one of the first reports to provide insights into the long-term use of healthcare and general functioning of Australian AYA cancer survivors, relative to a comparison group from the general community who have not had cancer. Our questionnaire probed survivors’ patterns of self-reported healthcare use in considerable detail, which adds to existing knowledge available through registry-based studies [53,54]. Several study limitations warrant consideration. Our sample was modest in size relative to international, registry-based cohort samples, and our convenience-based comparison group was not matched to our survivor group other than their recruitment from the same geographical catchment area. In particular, the higher proportion of females in our comparison group may have influenced the rates of HCU seen in our cohort of AYAs without cancer. Our comparison group was also more diverse than our cancer survivor cohort in terms of country of birth and language spoken at home. While this may reflect the high degree of diversity found in the Australian university sector (from which many of our comparisons were recruited) [66], it may also point to the relative lack of representativeness of the cancer survivors, likely at least in part due to our eligibility criteria requiring English fluency, as contemporaneous data indicated that approximately 58% of 12–24 year-old hospital patients from within the local health district our survivors were recruited from spoke English as a first language (81,659/140,911; Personal Communication, May 2018) [67].

Our comparison group may not have been completely representative of the Australian population of AYAs without cancer. Given that we recruited through a local university, our comparison group may have been more highly educated and of a higher socioeconomic status than the general AYA population. Observed differences in the two groups may therefore have been partly a result of our recruitment strategy.

Our questionnaire method relied upon retrospective self-report which is subject to bias and inaccuracies. Though comprehensive, our questionnaire did not ask about several specialist health professions (e.g., dental care) that may also be important for long-term medical care in survivorship. While we recruited our survivor group from a metropolitan hospital with a co-located AYA-specific Youth Cancer Service, we did not ask survivors to specify where they accessed services from (e.g., a hospital-delivered psychologist versus private practice clinical psychologists in the community), which precluded us undertaking analyses according to their primary site of cancer care. Given that we recruited AYA survivors through survivorship clinics, who were on average only a few years post-treatment, our sample does not represent cancer survivors who are lost to follow-up, and further into long-term survivorship, who may have different patterns of HCU. It is likely that being closer to the completion of cancer treatment may afford survivors relatively easier access to services based at, or linked with, their treating hospital. We also did not explore barriers AYAs can experience to accessing care [12], whether care was accessed or not. This limits the conclusions we can draw about the access afforded to survivors through the hospital setting. We also did not collect data on whether or not survivors were experiencing any ongoing late effects; this limits our ability to gauge the appropriateness of reported HCU relative to their needs, and for our survivor group means that we are unable to determine
whether their HCU might have been for screening, intervention for late effects/cancer-related sequelae, or for something entirely independent. It is also possible that AYAs who chose to participate in our study were more highly functioning relative to non-respondents. It is also possible that participating AYAs were more motivated to participate in this study. This may reflect that they actually had more difficulties or increased HCU relative to non-respondents. However, data from other studies using similar cohort methodology and cross-sectional designs have shown that young survivors who participated in those studies were representative of the broader survivor population, which provides some confidence in these data [68,69].

Our cross-sectional design means that we cannot draw conclusions about whether HCU had any causal impact on AYAs mental health or general functioning. Rather than healthcare, it is also plausible that we recruited a particularly high-functioning survivor sample, as other studies have noted poorer perceived health among long-term AYA cancer survivors [47]. Alternatively, it could also be that our comparison group, many of whom were tertiary and University students, was experiencing higher rates of untreated psychological distress and stress [1]. Finally, we did not measure a number of individual factors (e.g., health literacy, perceptions of healthcare need, motivation/engagement with healthcare) or sociodemographic factors (e.g., family/social resources and support, financial resources, transportation, living situation and mobility) which may have an important bearing on AYAs’ ability to successfully access and engage with healthcare services [70].

4.2. Future Directions

4.2.1. Mental Health Support into Long-Term Survivorship

Cancer aside, AYAs aged 18–25 years are the group most likely to experience mental health disorders, yet they are the group for whom this is the least likely to be detected or appropriately treated [71,72]. Our AYA cancer survivors reported relatively low rates of psychological distress. While patterns of distress did not markedly differ further into longer-term cancer survivorship, rates of accessing mental healthcare services did appear to lessen among survivors with greater time since treatment. Many Youth Cancer Services in Australia continue to offer free, hospital-delivered psychological support several years into survivorship, including using telehealth technologies to minimize barriers to accessing this support [58,73]. However, Australian Youth Cancer Services do not all continue to directly offer mental health and psychological support up to and beyond five years post-diagnosis [30], and access to a dedicated psychologist, let alone psychiatry, also remains a challenge for most of the Australian long-term follow-up survivorship care clinics for AYA survivors managed in the pediatric system [27]. As survivors move further from hospital-delivered care, longer-term cancer survivors may therefore experience a similar gap in mental healthcare to their community-based counterparts. Unlike hospital-delivered psychosocial care, which is largely free for cancer survivors, financial cost becomes a significant barrier for AYAs accessing mental health support delivered in the community, for example through private-practice clinical psychologists [74].

AYA survivors whose mental healthcare needs remain unmet are a vulnerable subgroup who remain at high risk of poor quality of life [54]. Recent Australian reports have highlighted that when seeking help with mental health issues, AYAs in the general community report greatest preference for consulting with a GP they know and trust for initial support, over other healthcare professionals (such as a school counsellor, telephone counselling line, or adolescent mental health service) [75]. This is also consistent with established frameworks highlighting the core role of primary care in facilitating access to mental healthcare in the community [76]. Our findings indicated that only a minority of AYA survivors (and comparison AYAs) reported having recently engaged with a GP. For survivors, it is possible that further into survivorship, as they move away from relying on hospital-delivered healthcare services, these relatively low rates of GP engagement could become more problematic in terms of facilitating their access to ongoing, community-delivered mental healthcare. It may be appropriate to expect a higher rate of engagement
with GPs among survivors relative to their peers without a cancer history, given survivors’ likelihood of late effects emerging even several decades after cancer treatment completion [29]. In fact, recent models of optimal long-term survivorship care for AYAs have advocated for GPs in primary care playing a more active role in the ongoing surveillance and management of survivors’ late effects as they move further away from the hospital system [27,29,77]. Determining optimal pathways to ensure AYA cancer survivors continue to be able to access evidence-based mental healthcare is critical. Given that our study examined a cohort of AYAs prior to the onset of COVID-19, it will be important to examine how exposure to models of remotely-delivered virtual care may change and even enhance how survivors continue to access tailored survivorship care into the future [58,78].

Routine screening and mental health follow-up into long-term survivorship is also critical to continue to address survivors’ psychotropic medication use and needs [73,79]. Our survivors reported less distress yet relatively high rates of psychotropic medication use relative to the community comparison group. The issue of psychotropic medication prescription—and its ongoing monitoring/surveillance—in cancer survivorship highlights the broader problem of whether and how best to transition (mental) healthcare services in survivorship from the acute, specialist hospital setting to community-delivered, general practice settings. De-prescribing, a process of monitoring medication use after prescription and discontinuing where necessary, is particularly salient for AYAs whose mental health needs are expected to greatly evolve over time [80]. Even in adult oncology there is a lack of data on how psychotropic medications are prescribed and monitored among patients over time [63,81]. For example, if a young survivor is prescribed an anti-depressant medication by their oncology team during active cancer treatment, it is not clear whether, when, how, and to whom the responsibility for monitoring this medication use might be transferred. Future studies should explore the appropriateness of medication usage for AYAs in survivorship.

4.2.2. Access versus Accessibility

Finally, our data must be considered in the context of a broader discussion around how individuals successfully access healthcare services. Based on a wealth of data documenting AYAs’ unique developmental and healthcare-related needs, recent international literature has emphasized the development of youth-friendly, age-appropriate cancer services for AYAs [19,20,23,25,30,82]. Recent data have highlighted that AYA-specific, age-appropriate health services are a common (unmet) need [20,34,83], and that having access to such services and fewer unmet health- and healthcare-related needs may lead to less distress and better quality of life [21,24,54]. The sample of AYAs in this study was linked to a large metropolitan hospital site with a specialist AYA service, which may have meant that our survivors had better access to age-appropriate health services relative to other Australian survivors. This may reflect the high-quality of a tailored, age-appropriate, AYA-focused model of cancer care. When stratified by survivors’ ongoing level of medical risks into longer-term survivorship, such models may help bridge the gap between what survivors want, need, and what survivorship care is able to provide them with [27,32].

There is a lack of evidence-based strategies with demonstrated effectiveness in enhancing AYAs’ access to primary and community-delivered healthcare [84,85]. Ultimately, even optimally-designed, youth-friendly healthcare services are likely not enough on their own to bridge all of the barriers to accessing healthcare that are likely exist for AYA cancer survivors. Successful healthcare access relies on an interaction between the characteristics of healthcare services themselves, and characteristics of the individuals trying to access them, including their ability to perceive their healthcare needs, seek and reach the healthcare services, pay for the healthcare services, and ultimately engage with them [70]. As a group, AYAs may be at risk for poor health literacy [14,15], and prior studies have shown links between lower education and suboptimal HCU in survivorship, even when survivors are experiencing severe or life-threatening late effects [51,52]. AYAs must also want to engage with healthcare services: recent Australian reports indicate that AYAs are most likely to
prefer to turn to friends and family for help with mental health concerns, over more formal avenues of support [86]. Family resources and supports—which may include family-level health literacy [87] and the provision of logistical supports by parents/caregivers such as transport to appointments and financial support [88]—are also likely to be critical to facilitating survivors’ ongoing engagement with healthcare. Future research is needed to examine how AYA and family resources, levels of health literacy, and levels of trust and engagement with the healthcare system, may impact the extent to which AYAs proactively seek out, and subsequently use these services. Whether accessing such AYA-targeted services ultimately leads to a better ‘match’ between recommended and appropriate HCU offered to—and actually taken up by—survivors is a topic for future research.

5. Conclusions

Our survivor cohort reported higher HCU across multiple domains compared with a community-based comparison group. Relative to the comparison group, survivors reported less distress in terms of depression and anxiety symptoms, and showed positive general functioning, including similar work/study participation, similar perceived health-related quality of life, and greater engagement with hobbies and social activities. Several survivor subgroups, including females, those with brain/solid tumors, and those who had finished treatment more recently, reported greater recent use of healthcare. Greater HCU was linked with better perceived health-related quality of life. Understanding how to engage AYA survivors in survivorship care that is appropriate, tailored to their needs, and delivered in a way they are motivated and able to access remains a challenge for the field.

Supplementary Materials: The following materials are available online at https://www.mdpi.com/article/10.3390/cancers13215270/s1, Table S1. Proportion of AYAs who reported having accessed mental healthcare services according to participant group and DASS-21 symptom score severity; Table S2. Patterns of psychotropic medication use reported by adolescents and young adults, according to other forms of mental healthcare services they reported accessing; Table S3. Multivariable linear regressions examining relationships between healthcare use (HCU) and general functioning outcomes.

Author Contributions: Conceptualization, U.M.S.-D., C.E.W., S.M.S., A.A., M.O., and R.J.C.; data curation, U.M.S.-D., M.W.D., C.S., and N.D.; formal analysis, U.M.S.-D., M.W.D., and N.D.; funding acquisition, C.E.W., U.M.S.-D., R.J.C., S.M.S., A.A., and M.O.; investigation, U.M.S.-D., C.E.W., R.J.C., R.V., K.F., and A.A.; methodology, U.M.S.-D., C.E.W., S.M.S., A.A., M.O., R.V., and R.J.C.; project administration, U.M.S.-D., C.E.W., K.F., and R.J.C.; resources, U.M.S.-D. and C.E.W.; software, M.W.D.; supervision, U.M.S.-D., C.E.W., R.J.C., S.M.S., and A.A.; visualization, M.W.D., U.M.S.-D., and N.D.; writing—original draft preparation, U.M.S.-D., C.S., C.E.W., M.W.D., and N.D.; writing—review and editing, U.M.S.-D., C.E.W., C.S., M.W.D., S.M.S., A.A., M.O., R.V., N.D., K.F., and R.J.C. All authors have read and agreed to the published version of the manuscript.

Funding: This study was partially funded through project funding awarded for the Recapture Life, co-funded by a beyond blue and Cancer Australia project grant (ID: 1022686). Ursula Sansom-Daly is supported by an Early Career Fellowship from the Cancer Institute of New South Wales (ID: 14/ECF/1-11, followed by 2020/ECF1163) and an Early Career Fellowship from the National Health and Medical Research Council of Australia (APP1111800). Claire Wakefield is supported by a Career Development Fellowship from the National Health and Medical Research Council of Australia (APP1143767), and an Early Career Fellowship from the Cancer Institute of New South Wales (ID: 11/ECF/3-43). Christina Signorelli is supported by an Early Career Fellowship from the Cancer Institute of New South Wales (ID: 2020/ECF1144). The Behavioural Sciences Unit is proudly supported by the Kids with Cancer Foundation, by the Kids Cancer Alliance, as well as a Cancer Council New South Wales Program Grant (PG16-02) with the support of the Estate of the Late Harry McPaul.

Institutional Review Board Statement: This study was conducted according to the guidelines of the Declaration of Helsinki. Our research protocol was reviewed and approved on 26th April, 2012 by the South Eastern Sydney Local Health District Ethics Committee (Reference: HREC/12/POWH/136) as
well as by the Human Research Ethics Advisory Panel of the School of Psychology, UNSW Sydney, who provided approval for recruitment of our control group (Reference: File 2892).

Informed Consent Statement: Informed consent was obtained from all subjects involved in this study.

Data Availability Statement: The data presented in this study are available upon reasonable request from the corresponding author, as is the full study protocol and the study materials. The data are not publicly available due to restrictions within the ethical approval.

Acknowledgments: We would like to thank Stephanie Arteaga, Kate Awford, Emma Doolan, Gadiel Dumla, Sarah Ellis, Holly Evans, Ellen Yanxiang Gan, Kate Hetherington, Fiona Maguire, Kate Marshall, Sanaa Mathur, Brittany McGill, Catherine O’Dwyer, Eden Robertson, Maria Schaffer, Helen Wilson, Janine Vetsch, and Eric Xu for their contributions to this study. The Recapture Life study was endorsed by the Psycho-Oncology Cooperative Research Group (PoCoG), Australia, as well as the Clinical Oncology Society of Australasia’s (COSA) AYA Cancer Research Steering Committee.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sansom-Daly, U.M.; Wakefield, C.E.; Robertson, E.G.; McGill, B.C.; Wilson, H.L.; Bryant, R.A. Adolescent and young adult cancer survivors’ memory and future thinking processes place them at risk for poor mental health. Psychooncology 2018, 27, 2709–2716. [CrossRef]

2. Vetsch, J.; Wakefield, C.E.; McGill, B.C.; Cohn, R.J.; Ellis, S.J.; Stefanic, N.; Sawyer, S.M.; Zebrack, B.; Sansom-Daly, U.M. Educational and vocational goal disruption in adolescent and young adult cancer survivors. Psychooncology 2018, 27, 532–538. [CrossRef]

3. Sansom-Daly, U.M.; Wakefield, C.E. Distress and adjustment among young adults with cancer: An empirical and conceptual review. Transl. Pediatr. 2013, 2, 167–197.

4. Kessler, R.C.; Berglund, P.; Demler, O.; Jin, R.; Merikangas, K.R.; Walters, E.E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 2005, 62, 593–602. [CrossRef]

5. International Agency for Research on Cancer. GLOBOCAN: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available online: https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012 (accessed on 23 April 2020).

6. Jensen, M.V.; Rugbjerg, K.; de Fine Licht, S.; Johansen, C.; Schmiegelow, K.; Andersen, K.K.; Winther, J.F. Endocrine Late Effects in Post-Treatment Adolescent and Young Adult Cancer Survivors. J. Adolesc. Young Adult Oncol. 2018, 7, 466–467. [CrossRef]

7. Gupta, S. Adolescents and young adults with cancer and the risk of subsequent primary neoplasms: Not just big children. Lancet Oncol. 2019, 20, 466–467. [CrossRef]

8. Zhang, Y.; Goddard, K.; Spinelli, J.J.; Gotay, C.; McBride, M.L. Risk of Late Mortality and Second Malignant Neoplasms among 5-Year Survivors of Young Adult Cancer: A Report of the Childhood, Adolescent, and Young Adult Cancer Survivors Research Program. J. Cancer Epidemiol. 2012, 2012, 103032. [CrossRef]

9. Seitz, D.C.; Besier, T.; Debatis, K.-M.; Grabow, D.; Dielwein, U.; Hinz, A.; Kaatsch, P.; Goldbeck, L. Posttraumatic stress, depression and anxiety among adult long-term survivors of cancer in adolescence. Eur. J. Cancer 2010, 46, 1596–1606. [CrossRef]

10. Kwak, M.; Zebrack, B.J.; Meeks, K.A.; Embly, L.; Aguilar, C.; Block, R.; Hayes-Lattin, B.; Li, Y.; Butler, M.; Cole, S. Trajectories of Psychological Distress in Adolescent and Young Adult Patients With Cancer: A 1-Year Longitudinal Study. J. Clin. Oncol. 2013, 31, 2160–2166. [CrossRef]

11. Thewes, B.; KaaL, S.E.J.; Custers, J.A.E.; Manten-Horst, E.; Jansen, R.; Servaes, P.; van der Graaf, W.T.A.; Prins, J.B.; Husson, O. Prevalence and correlates of high fear of cancer recurrence in late adolescents and young adults consulting a specialist adolescent and young adult (AYA) cancer service. Support. Care Cancer 2018, 26, 1479–1487. [CrossRef]

12. Jones, J.M.; Fitch, M.; Bongard, J.; Maganti, M.; Gupta, A.; D’Agostino, N.; Korenblum, C. The Needs and Experiences of Post-Treatment Adolescent and Young Adult Cancer Survivors. J. Clin. Med. 2020, 9, 1444. [CrossRef]

13. Deloitte Access Economics. The Economic Cost of Cancer in Adolescents and Young Adults. 2018. Available online: https://www.canteen.org.au/wp-content/uploads/2020/10/Canteen_Deloitte_costofcancer_final_web.pdf (accessed on 20 October 2020).

14. Lin, M.; Sansom-Daly, U.M.; Wakefield, C.E.; McGill, B.C.; Cohn, R.J. Health Literacy in Adolescents and Young Adults: Perspectives from Australian Cancer Survivors. J. Adolesc. Young Adult Oncol. 2017, 6, 150–158. [CrossRef]

15. Sansom-Daly, U.M.; Lin, M.; Robertson, E.G.; Wakefield, C.E.; McGill, B.C.; Girgis, A.; Cohn, R.J. Health Literacy in Adolescents and Young Adults: An Updated Review. J. Adolesc. Young Adult Oncol. 2016, 5, 106–118. [CrossRef]

16. Hewitt, M.; Rowland, J.H. Mental health service use among adult cancer survivors: Analyses of the National Health Interview Survey. J. Clin. Oncol. 2002, 20, 4581–4590. [CrossRef]

17. Canteen Australia. Australian Youth Cancer Framework: For Adolescents and Young Adults with Cancer; Canteen Australia: Sydney, Australia, 2017.
18. Zebrack, B.; Mathews-Bradjshaw, B.; Siegel, S. Quality cancer care for adolescents and young adults: A position statement. J. Clin. Oncol. 2010, 28, 4862–4867. [CrossRef]
19. Whiteson, M. The Teenage Cancer Trust—advocating a model for teenage cancer services. Eur. J. Cancer 2003, 39, 2688–2693. [CrossRef]
20. Sawyer, S.M.; McNeil, R.; Thompson, K.; Orme, L.M.; McCarthy, M. Developmentally appropriate care for adolescents and young adults with cancer: How well is Australia doing? Support. Care Cancer 2019, 27, 1783–1792. [CrossRef]
21. Bradford, N.; Walker, R.; Cashion, C.; Henney, R.; Yates, P. Do specialist youth cancer services meet the physical, psychological and social needs of adolescents and young adults? A cross sectional study. Eur. J. Oncol. Nurs. 2020, 44, 101709. [CrossRef]
22. Osborn, M.; Johnson, R.; Thompson, K.; Anazodo, A.; Albritton, K.; Ferrari, A.; Stark, D. Models of care for adolescent and young adult cancer programs. Pediatr. Blood Cancer 2019, 66, e27991. [CrossRef]
23. Osborn, M.; Little, C.; Bowering, S.; Orme, L. Youth Cancer Services in Australia: Development and Implementation. International Perspectives on Adolescent and Young Adult Oncology, Part 3. J. Adolesc. Young Adult Oncol. 2013, 2, 118–124. [CrossRef]
24. Skaczkowski, G.; White, V.; Thompson, K.; Bibby, H.; Coory, M.; Pinkerton, R.; Orme, L.M.; Conyers, R.; Phillips, M.B.; Osborn, M.; et al. Do Australian adolescents’ and young adults’ experiences of cancer care influence their quality of life? Psychooncology 2018, 27, 990–997. [CrossRef]
25. White, V.; Skaczkowski, G.; Thompson, K.; Bibby, H.; Coory, M.; Pinkerton, R.; Nicholls, W.; Orme, L.M.; Conyers, R.; Phillips, M.B. Experiences of Care of Adolescents and Young Adults with Cancer in Australia. J. Adolesc. Young Adult Oncol. 2018, 7, 315–325. [CrossRef] [PubMed]
26. Van Breeschoten, J.; De Abreu Lourenco, R.; Signorelli, C.; Haas, M.; Cohn, R.J.; Wakefield, C.E.; Fardell, J.E. Patterns and drivers of health care use in long-term childhood cancer survivors: A systematic review. Crit. Rev. Oncol. Hematol. 2017, 120, 60–76. [CrossRef] [PubMed]
27. Signorelli, C.; Wakefield, C.E.; McLoone, J.K.; Fardell, J.E.; Lawrence, R.A.; Osborn, M.; Truscott, J.; Tapp, H.; Cohn, R.J.; Group, A.S.S. Models of childhood cancer survivorship care in Australia and New Zealand: Strengths and challenges. Asia Pac. J. Clin. Oncol. 2017, 13, 407–415. [CrossRef]
28. Pollack, L.A.; Greer, G.E.; Rowland, J.H.; Miller, A.; Doneski, D.; Coughlin, S.S.; Stovall, E.; Ulman, D. Cancer survivorship: A new challenge in comprehensive cancer control. Cancer Causes Control. 2005, 16 (Suppl. S1), 51–59. [CrossRef] [PubMed]
29. Signorelli, C.; Wakefield, C.E.; McLoone, J.K.; Fardell, J.; Jones, J.M.; Turpin, K.H.; Emery, J.; Michel, G.; Downie, P.; Skeen, J.E.; et al. Childhood cancer survivorship: Barriers and preferences. BMJ Support. Palliat Care 2019. [CrossRef] [PubMed]
30. Patterson, P.; Allison, K.R.; Bibby, H.; Thompson, K.; Lewin, J.; Briggs, T.; Walker, R.; Osborn, M.; Plaster, M.; Hayward, A.; et al. The Australian Youth Cancer Service: Developing and Monitoring the Activity of Nationally Coordinated Adolescent and Young Adult Cancer Care. Cancers 2021, 13, 2675. [CrossRef]
31. Taylor, R.M.; Fern, L.A.; Barber, J.; Alvarez-Galvez, J.; Feltbower, R.; Lea, S.; Martins, A.; Morris, S.; Hooker, L.; Gibson, F.; et al. Longitudinal cohort study of the impact of specialist cancer services for teenagers and young adults on quality of life: Outcomes from the BRIGHTLIGHT study. BMJ Open 2020, 10, e038471. [CrossRef]
32. Signorelli, C.; Wakefield, C.; Johnston, K.A.; Fardell, J.; Brierley, M.-E.E.; Schaffer, M.; Thornton-Benko, E.; Girgis, A.; Wallace, W.H.; et al. Re-Engage: A Novel Nurse-Led Program for Survivors of Childhood Cancer Who Are Disengaged From Cancer-Related Care. J. Natl. Comp. Cancer Netw. 2020, 18, 1067–1074. [CrossRef]
33. Smits-Seemann, R.R.; Kaul, S.; Zamora, E.R.; Wu, Y.P.; Kirchhoff, A.C. Barriers to follow-up care among survivors of adolescent and young adult cancer. J. Clin. Oncol. 2017, 35, 2688–2693. [CrossRef]
34. Hydeman, J.A.; Uwazurike, O.C.; Adeyemi, E.I.; Beaupin, L.K. Survivorship needs of adolescent and young adult cancer survivors: A concept mapping analysis. J. Cancer Surviv. Res. Pract. 2019, 13, 34–42. [CrossRef]
35. Bradford, N.; Henney, R.; Cashion, C.; Holland, L.; Walker, R. What cancer survivorship services do young people want? Aust. J. Cancer Nurs. 2020, 21, 9–16. [CrossRef]
36. Zebrack, B.J.; Corbett, V.; Embry, L.; Aguilar, C.; Meeske, K.A.; Hayes-Lattin, B.; Block, R.; Zeman, D.T.; Cole, S. Psychological distress and unsatisfied need for psychosocial support in adolescent and young adult cancer patients during the first year following diagnosis. Psychooncology 2014, 23, 1267–1275. [CrossRef]
37. Parsons, H.M.; Harlan, L.C.; Lynch, C.F.; Hamilton, A.S.; Wu, X.C.; Kato, I.; Schwartz, S.M.; Smith, A.W.; Keel, G.; Keegan, T.H. Impact of cancer on work and education among adolescent and young adult cancer survivors. J. Clin. Oncol. 2019, 37, 2393–2400. [CrossRef] [PubMed]
38. Aubin, S.; Barr, R.; Rogers, P.; Schacter, B.; Bielack, S.S.; Ferrara, A.; Manchester, R.A.; McMaster, K.; Morgan, S.; Pattison, M.; et al. What Should the Age Range Be for AYA Oncology? J. Adolesc. Young Adult Oncol. 2011, 1, 3–10. [CrossRef]
39. Tully, P.J.; Zajac, I.T.; Venning, A.J. The structure of anxiety and depression in a normative sample of younger and older Australian adolescents. J. Abnorm. Child. Psychol. 2009, 37, 717–726. [CrossRef] [PubMed]
40. Loh, S.Y.; Tan, F.L.; Xavier, M. Depression, Anxiety And Stress In Women With Breast Cancer: Effect Of A 4-Week Self Management Intervention. Malays. J. Psychiatry 2009, 18, 58–66.
41. Lovibond, P.F.; Lovibond, S.H. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav. Res. Ther. 1995, 33, 335–343. [CrossRef]
42. Reulen, R.C.; Zeegers, M.P.; Jenkinson, C.; Lancashire, E.R.; Winter, D.L.; Jenney, M.E.; Hawkins, M.M.; Reulen, R.C.; Zeegers, M.P.; Jenkinson, C.; et al. The use of the SF-36 questionnaire in adult survivors of childhood cancer: Evaluation of data quality, score reliability, and scaling assumptions. Health Qual. Life Outcomes 2006, 4, 77. [CrossRef]

43. Macias, C.; Gold, P.B.; Ongur, D.; Cohen, B.M.; Panch, T. Are Single-Item Global Ratings Useful for Assessing Health Status? J. Clin. Psychol. Med. Settings 2015, 22, 251–264. [CrossRef]

44. Altman, D.G.; Royston, P. The cost of dichotomising continuous variables. BMJ 2006, 332, 1080. [CrossRef]

45. Sansom-Daly, U.M.; Wakefield, C.E.; Bryant, R.A.; Butow, P.; Sawyer, S.; Patterson, P.; Anazodo, A.; Thompson, K.; Cohn, R.J. Online group-based cognitive-behavioural therapy for adolescents and young adults after cancer treatment: A multicenter randomised controlled trial of Recapture Life-AYA. BMC Cancer 2012, 12, 339. [CrossRef]

46. Australian Institute of Health Welfare. Cancer in Adolescents and Young Adults in Australia; AIHW: Canberra, Australia, 2018.

47. Kirchhoff, A.C.; Spraker-Perlman, H.L.; McFadden, M.; Warner, E.L.; Oeffinger, K.C.; Wright, J.; Kinney, A.Y. Sociodemographic Disparities in Quality of Life for Survivors of Adolescent and Young Adult Cancers in the Behavioral Risk Factor Surveillance System. J. Adolesc. Young Adult Oncol. 2014, 3, 66–74. [CrossRef]

48. Fardell, J.E.; Wakefield, C.E.; Patterson, P.; Lum, A.; Cohn, R.J.; Pini, S.A.; Sansom-Daly, U.M. Narrative Review of the Educational, Vocational, and Financial Needs of Adolescents and Young Adults with Cancer: Recommendations for Support and Research. J. Adolesc. Young Adult Oncol. 2018, 7, 143–147. [CrossRef] [PubMed]

49. Oeffinger, K.C.; Mertens, A.C.; Hudson, M.M.; Gurney, J.G.; Casillas, J.; Yeazel, M.W.; Robison, L.L. Health care of young adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. J. Cancer Surviv. 2012, 6, 239–250. [CrossRef]

50. Oeffinger, K.C.; Hudson, M.M.; Landier, W. Survivorship: Childhood cancer survivors. Prim. Care 2009, 36, 743–780. [CrossRef] [PubMed]

51. Johnson, R.; Horne, B.; Feltbower, R.G.; Butler, G.E.; Glaser, A.W. Hospital attendance patterns in long term survivors of cancer. Arch. Dis. Child. 2004, 89, 374–377. [CrossRef] [PubMed]

52. Casillas, J.; Oeffinger, K.C.; Hudson, M.M.; Greenberg, M.L.; Yeazel, M.W.; Ness, K.K.; Henderson, T.O.; Robison, L.L.; Armstrong, G.T.; Liu, Q.; et al. Identifying Predictors of Longitudinal Decline in the Level of Medical Care Received by Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Health Serv. Res. 2015. [CrossRef] [PubMed]

53. Keegan, T.H.; Lichtensztajn, D.Y.; Kato, I.; Kent, E.E.; Wu, X.-C.; West, M.M.; Hamilton, A.S.; Zebrack, B.; Bellizzi, K.M.; Smith, A.W. Unmet adolescent and young adult cancer survivors information and service needs: A population-based cancer registry study. J. Cancer Surviv. 2012, 6, 54–60. [CrossRef]

54. Wilder Smith, A.; Keegan, T.; Hamilton, H.; Lynch, C.; Wu, X.-C.; Schwartz, S.M.; Kato, I.; Cress, R.; Harlan, L. AYA HOPE Study Collaborative Group. Understanding care and outcomes in adolescents and young adults with cancer: A review of the AYA HOPE study. Pediatr. Blood Cancer 2019, 66, e27486. [CrossRef] [PubMed]

55. Steele, J.R.; Wall, M.; Salkowski, N.; Mityb, P.; Kawashima, T.; Yeazel, M.W.; Hudson, M.M.; Robison, L.L.; Mertens, A.C. Predictors of risk-based medical follow-up: A report from the childhood cancer survivor study. J. Cancer Surviv. 2013, 7, 379–391. [CrossRef]

56. Yeazel, M.W.; Gurney, J.G.; Oeffinger, K.C.; Mertens, A.C.; Smith, A.W. Unmet adolescent and young adult cancer survivors information and service needs: A population-based cancer registry study. J. Cancer Surviv. 2012, 6, 239–250. [CrossRef]

57. McGorry, P.; Parker, A.; Purcell, R. Youth Mental Health Services. InPsych 2006, 24.

58. Sansom-Daly, U.M.; Bradford, N. Grappling with the “human” problem hiding behind the technology: Telehealth during and beyond COVID-19. Psychon Bull Rev 2020, 29, 1404–1408. [CrossRef]

59. Booth, M.; Bernard, D.; Quine, S.; Kang, M.; Usherwood, T.; Alperstein, G.; Beasley, L.; Bennett, D. Access to Health Care among NSW Adolescents: NSW Centre for the Advancement of Adolescent Health, The Children’s Hospital at Westmead: Sydney, Australia, 2002.

60. Brinkman, T.M.; Ullrich, N.J.; Zhang, N.; Green, D.M.; Zeltzer, L.K.; Lommel, K.M.; Brouwers, P.; Srivastava, D.K.; Jain, N.; Robison, L.L.; et al. Prevalence and predictors of prescription psychoactive medication use in adult survivors of childhood cancer: From the Childhood Cancer Survivor Study. J. Cancer Surviv. 2013, 7, 104–114. [CrossRef]

61. Deyell, R.J.; Lorenzi, M.; Ma, S.; Rassekh, S.R.; Collet, J.P.; Spinelli, J.J.; McBride, M.L. Antidepressant use among survivors of childhood, adolescent and young adult cancer: A report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program. Pediatr. Blood Cancer 2013, 60, 816–822. [CrossRef]

62. Johannsdottir, I.M.; Karlstad, O.; Loge, J.H.; Fossa, S.D.; Kiserud, C.; Skurtveit, S. Prescriptions of Antidepressants to Survivors of Cancer in Childhood, Adolescence, and Young Adulthood: A Population-Based Study. J. Adolesc. Young Adult Oncol. 2017, 6, 120–126. [CrossRef]

63. Sanjida, S.; Mulvogue, K.; Shaw, J.; Couper, J.; Kissane, D.; Pearson, S.-A.; Price, M.A.; Janda, M. What type and dose of antidepressants are cancer and non-cancer inpatients being prescribed: A retrospective case-control study at an Australian tertiary hospital. Support Care Cancer 2018, 26, 625–634. [CrossRef]

64. Ndso, D.H.; Ladas, E.J.; Bao, Y.; Cheng, B.; Nees, S.N.; Levine, J.M.; Kelly, K.M. Use of complementary and alternative medicine among children, adolescent, and young adult cancer survivors: A survey study. J. Pediatr. Hematol. Oncol. 2013, 35, 281–288. [CrossRef]
65. Thewes, B.; Butow, P.; Bell, M.L.; Beith, J.; Stuart-Harris, R.; Grossi, M.; Capp, A.; Dalley, D.; The FCR Study Advisory Committee. Fear of cancer recurrence in young women with a history of early-stage breast cancer: A cross-sectional study of prevalence and association with health behaviours. Support Care Cancer 2012, 20, 2651–2659. [CrossRef] [PubMed]

66. Coates, H.; Edwards, D.; Goedegebure, L.; Thakur, M.; van der Brugge, E.; van Vogt, F. Profiling Diversity of Australian Universities; LH Martin Institute and the Australian Council for Educational Research: Melbourne, Victoria, Australia, 2013.

67. Stephenson, J.; (Prince of Wales Hospital Diversity Unit). Languages used in South Eastern Sydney Local Health District (SESLHD). Personal communication, 2018.

68. Harlan, L.C.; Lynch, C.F.; Keegan, T.H.; Hamilton, A.S.; Wu, X.-C.; Kato, I.; West, M.M.; Cress, R.D.; Schwartz, S.M.; Smith, A.W. Recruitment and follow-up of adolescent and young adult cancer survivors: The AYA HOPE Study. J. Cancer Surviv. 2011, 5, 305–314. [CrossRef] [PubMed]

69. Rueegg, C.S.; Gianinazzi, M.E.; Michel, G.; Zważhelen, M.; von der Weid, N.X.; Kuehni, C.E.; Swiss Paediatric Oncology Group. No evidence of response bias in a population-based childhood cancer survivor questionnaire—Results from the Swiss Childhood Cancer Survivor Study. PloS ONE 2017, 12, e0176442. [CrossRef] [PubMed]

70. Levesque, J.-F.; Harris, M.F.; Russell, G. Patient-centred access to health care: Conceptualising access at the interface of health systems and populations. Int. J. Equity Health 2013, 12, 18. [CrossRef]

71. Hickie, I.B.; Davenport, T.A.; Naismith, S.L.; Scott, E.M.; Hadzi-Pavlovic, D.; Koschera, A. Treatment of common mental disorders in Australian general practice. Med. J. Aust. 2001, 175, S25–S30. [CrossRef]

72. Hickie, I.B.; Davenport, T.A.; Scott, E.M.; Hadzi-Pavlovic, D.; Naismith, S.L.; Koschera, A. Unmet need for recognition of common mental disorders in Australian general practice. Med. J. Aust. 2001, 175, S18–S24. [CrossRef] [PubMed]

73. Chalmers, J.A.; Sansom-Daly, U.M.; Patterson, P.; McCowage, G.; Anazodo, A. Psychosocial Assessment Using Telehealth in Adolescents and Young Adults With Cancer: A Partially Randomized Patient Preference Pilot Study. J.MIR Protoc. 2018, 7, e168. [CrossRef]

74. Schnyder, N.; Sawyer, S.M.; Orme, L.; Thompson, K.; Drew, S.; Dunt, D. Unmet need for healthcare services in adolescents and young adults with cancer and their parent carers. Support Care Cancer 2017, 25, 2229–2239. [CrossRef]

75. Booth, M.L.; Bernard, D.; Quine, S.; Kang, M.S.; Usherwood, T.; Alperstein, G.; Bennett, D.L. Access to health care among Australian adolescents young people’s perspectives and their sociodemographic distribution. J. Adolesc. Health 2004, 34, 97–103. [CrossRef]

76. Goldberg, D.; Huxley, P. Mental Illness in the Community: The Pathway to Psychiatric Care; Tavistock: London, UK, 1980.

77. McLoone, J.; Wakefield, C.; Sansom-Daly, U.; Thornton-Benko, E.; Govender, D.; Gabriel, M.; Walwyn, T.; Signorelli, C.; Johnston, K.; Cohn, R. The lived experience of children and adolescents with cancer. Aust. J. Gen. Pract. 2021, 50, 545–549. [CrossRef]

78. McLoone, J.; Wakefield, C.E.; Taylor, N.; Johnston, K.; Sansom-Daly, U.M.; Cohen, J.; O’Brien, T.A.; Cohn, R.J.; Signorelli, C. The COVID-19 pandemic: Distance-delivered care for childhood cancer survivors. Pediatr. Blood Cancer 2020, 67, e28715. [CrossRef] [PubMed]

79. Patterson, P.; Hardman, F.; Cheshire, J.; Sansom-Daly, U.M. Balancing risk with resilience: Using holistic screening and assessment approaches to address the mental health needs of adolescents and young adults with cancer. J. Cancer Surviv. 2011, 5, 305–314. [CrossRef] [PubMed]

80. Stephenson, J.; (Prince of Wales Hospital Diversity Unit). Languages used in South Eastern Sydney Local Health District (SESLHD). Personal communication, 2018.

81. Sanjida, S.; Janda, M.; Kissane, D.; Shaw, J.; Pearson, S.A.; DiSipio, T.; Couper, J. A systematic review and meta-analysis of prescribing practices of antidepressants in cancer patients. Psychooncology 2016, 25, 1002–1016. [CrossRef] [PubMed]

82. Fardell, J.E.; Patterson, P.; Wakefield, C.E.; Signorelli, C.; Cohn, R.J.; Anazodo, A.; Zebrack, B.; Sansom-Daly, U.M. A Narrative Review of Models of Care for Adolescents and Young Adults with Cancer: Barriers and Recommendations. J. Adolesc. Young Adult Oncol. 2018, 7, 148–152. [CrossRef]

83. Sawyer, S.M.; McNeil, R.; McCarthy, M.; Orme, L.; Thompson, K.; Drew, S.; Dunt, D. Unmet need for healthcare services in adolescents and young adults with cancer and their parent carers. Support Care Cancer 2017, 25, 2229–2239. [CrossRef]

84. Kang, M.; Bernard, D.; Usherwood, T.; Quine, S.; Alperstein, G.; Kerr-Roubicek, H.; Elliott, A.; Bennett, D. Primary health care for young people: Are there models of service delivery that improve access and quality. Youth Stud. Aust. 2006, 25, 49–59.

85. Kang, M.; Bernard, D.; Booth, M.; Quine, S.; Alperstein, G.; Usherwood, T.; Bennett, D. Access to primary health care for Australian young people: Service provider perspectives. Br. J. Gen. Pract. J. R. Coll. Gen. Pract. 2003, 53, 947–952.

86. Black Dog Institute and Mission Australia. Youth Mental Health Report: Youth Survey 2012–16; Black Dog Institute and Mission Australia: Sydney, Australia, 2017.

87. Gessler, D.; Juraskova, I.; Sansom-Daly, U.M.; Shepherd, H.L.; Patterson, P.; Muscat, D.M. Clinician-patient-family decision-making and health literacy in adolescents and young adults with cancer and their families: A systematic review of qualitative studies. Psychooncology 2019, 28, 1408–1419. [CrossRef] [PubMed]

88. Keegan, T.H.; Tao, L.; DeRouen, M.C.; Wu, X.C.; Prasad, P.; Lynch, C.F.; Shnorhavorian, M.; Zebrack, B.J.; Chu, R.; Harlan, L.C.; et al. Medical care in adolescents and young adult cancer survivors: What are the biggest access-related barriers? J. Cancer Surviv. Res. Pract. 2014, 8, 282–292. [CrossRef] [PubMed]